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Simple snoring is highly prevalent and should be considered a phenomenon distinct from sleep 
disordered breathing (SDB). Snoring is associated with cardiovascular disease (CVD) morbidity 
and mortality. Midlife women are at increased risk for snoring and cardiovascular disease, yet 
little is known about the relationships between these factors in this population. We propose and 
test a mechanistic model of snoring-related atherogenesis to explain these associations. This is 
the first study to examine the relationship in midlife women between objective and subjective 
snoring and C-reactive protein (CRP), a CVD biomarker, and the first study to characterize the 
correlates of snoring in midlife women. The full multi-ethnic sample included 300 women (52.07 
± 2.13 years, 44% African American) from the SWAN Sleep Study, ancillary to the Study of 
Women’s Health Across the Nation (SWAN). Objective snoring and apnea-hypopnea index 
(AHI) were measured in a subset of 241 participants on one night of in-home polysomnography. 
CRP was measured at the core SWAN visit temporally closest to the sleep study. Linear 
regression models examined the relationships between objectively-derived snoring index, a ratio 
of snore epochs to sleep epochs, and CRP in both the full sample and in postmenopausal women 
only. Objective and subjective snoring group differences in mean CRP were tested using 
ANCOVA. Frequency of objective snoring was associated with higher CRP in postmenopausal 
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 women only. Snoring was not significantly associated with CRP in the full sample. The 
relationship between snoring and CRP was not moderated by AHI or race. There were no group 
differences in CRP between objective or subjective snoring groups after adjusting for all 
covariates. Characterization of the sample revealed that simple snorers are distinct from women 
with SDB. Simple snorers also differed from absent snorers on key CVD risk factors, including 
higher BMI, systolic blood pressure, and number of metabolic syndrome criteria. There was little 
agreement between objective snoring frequency and subjective snoring self-report. These 
findings show that simple snoring should be considered a distinct construct from SDB and 
measured objectively alongside AHI in future studies. Snoring represents a unique and 
understudied risk factor for CVD, particularly in postmenopausal women. 
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1.0 INTRODUCTION 
 
 
 
 
Simple snoring occurs separately from sleep disordered breathing (SDB) disorders. This form of 
snoring does not co-occur with the hypoxia, severe flow limitation, and apnea/hypopnea events 
that characterize SDB. While snoring is anecdotally linked to men, rates of self-reported snoring 
in adult women are moderate and increase substantially in midlife (e.g. Young et al., 1993; 
Lugaresi et al., 1980; National Sleep Foundation, 2007). However, the reasons for increased 
snoring in midlife women remain understudied and unclear. The downstream consequences of 
snoring to cardiovascular risk suggest that midlife women are an important and high-risk 
population for snoring and cardiovascular disease researchers. 
Snoring may be an important component of the mechanistic pathways to atherogenesis 
and subsequent CVD mortality. Studies spanning the past four decades have found associations 
between both self-reported and objective snoring and cardiovascular and cardiometabolic risk 
factors, including carotid atherosclerosis (Lee et al., 2008) and the metabolic syndrome (Troxel 
et al., 2010). In the current study, we propose an inflammation-endothelial dysfunction model of 
snoring-related atherogenesis to explain these associations. We first provide the rationale for 
examining this model in midlife women and outline the prevalence of snoring in women, 
including age and race differences, and changes in CVD risk accompanying the menopausal 
transition. Next, we define snoring and SDB and review the currently understood associations 
between snoring and disease risk. We then review evidence linking snoring vibrations to 
inflammation and endothelial dysfunction. Finally, we discuss the role of the current study in 
testing and refining the proposed snoring-related atherogenesis model in midlife women. 
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1.1 RATIONALE FOR EXAMINING SNORING AND CVD RISK FACTORS IN 
MIDLIFE WOMEN 
 
 
1.1.1 Prevalence of Self-Reported Snoring: Age and Race Differences 
 
 
Simple snoring is a common disorder, with prevalence of habitual snoring in middle-aged adults 
ranging from 19% to 59% (Lugaresi et al., 1980; Hiestand et al., 2006; Fitzpatrick et al., 1993). 
While snoring is often considered a male phenomenon, it has an estimated lifetime habitual 
prevalence of 28% in adult women (Young et al., 1993). The prevalence of snoring in women is 
age-dependent and increases dramatically during midlife. The 2007 National Sleep Foundation’s 
Sleep in America poll of women found that the prevalence of self-reported snoring increased 
from 33% in women aged 18-24 to 59% in women aged 45-54. A 2006 population-based study 
of 6,817 women in Sweden found that snoring was strongly age-dependent, with the highest 
prevalence of self-reported habitual snoring in women aged 50-59 years (Svensson et al., 2006). 
Earlier cross-sectional studies reported that habitual snoring increased from 5% in women under 
30 to roughly 25% in women over 45 (Lugaresi et al., 1980). Increased snoring prevalence may 
be related to hormonal or morphological changes associated with the menopausal transition, 
indicating that midlife women may be uniquely predisposed to the risk factors associated with 
snoring.  
 In addition to these age differences, some race differences have also been observed in 
subjective snoring rates. Self-reported snoring and sleep disordered breathing prevalence are 
significantly increased in African American women compared to non-Hispanic white women 
(O’Connor et al., 2003; Redline et al., 1997; Scharf et al., 2004; Ram et al., 2010). 
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 Cephalometric analysis suggests that differences in craniofacial morphology may underlie these 
differences (Lee, Ramirez, & Will, 1997; Redline et al., 1997). However, it is currently unknown 
whether objective measures of snoring differ on the basis of race. 
 
 
1.1.2 CVD Risk and the Menopausal Transition 
 
 
Previous research has demonstrated that postmenopausal women are at greater risk for 
cardiovascular events and coronary artery disease than premenopausal women (Kannel et al., 
1976; Gohlke-Barwolf, 2000; Miller et al., 2003), although the mechanisms of menopause on 
disease risk remain unclear. One study found that postmenopausal women exhibit significantly 
higher prevalence of carotid atherosclerosis (54%) than premenopausal women (25%; Sutton-
Tyrrell, 1998). A similar study found that postmenopausal women had a 1.84-fold increased risk 
of carotid atherosclerotic lesions compared to premenopausal women, despite lower mean rates 
of smoking in the postmenopausal group (Bonithon-Kopp et al., 1989). In the Study of Women’s 
Health Across the Nation, increased low-density lipoprotein (LDL) cholesterol, total cholesterol, 
and apolipoprotein B were observed in conjunction with the menopausal transition (Matthews et 
al., 2009). Other risk factors identified in postmenopausal women have included smoking, 
obesity, hypertension, and sedentary lifestyle (Gohlke-Barwolf, 2000; Miller et al., 2003). Given 
the increased prevalence of self-reported snoring during and after the menopausal transition, it is 
conceivable that snoring represents an additional risk factor for CHD in postmenopausal women. 
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 1.2 DEFINITIONS OF SNORING AND OBSTRUCTIVE SLEEP APNEA 
 
 
Snoring is a dynamic event resulting from a decrease in the sagittal diameter of the oropharynx, 
followed by high frequency oscillations of the soft palate, pharyngeal walls, epiglottis, and 
tongue (Ayappa & Rapoport, 2003; Liistro et al., 1991, Figure 1).  
 
 
 
 
 
 
Figure 1. Anatomical Diagram of the Structures Involved in Snoring. 
 
 
 
Decreased general muscle tone associated with sleep appears to cause some airflow limitation in 
snorers and non-snorers alike. However, snorers demonstrate an additional decrease in upper 
airway tone past a critical cross-sectional threshold, which then induces the soft palate 
oscillations of snoring (Liistro et al., 1991). Factors correlated with snoring include increased 
age, obesity, neck adiposity, supine sleeping position, alcohol-related decreased muscle tone, 
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 inflammation of nasal and pharyngeal passageways due to active or passive smoke exposure, and 
upper airway infection (Schmidt-Nowara et al., 1990; Gohlke-Barwolf, 2000; Miller et al., 
2003).  
Despite the high prevalence of simple snoring, respiratory sleep research has largely 
focused on SDB, particularly obstructive sleep apnea/hypopnea syndrome (OSAHS, also called 
OSA). OSAHS is a sleep disorder wherein extreme sleep-related pharyngeal collapsibility leads 
to partial or full occlusion or obstruction of the upper airway, resulting in hypoxemia, reduced 
inspiratory airflow, intra-thoracic pressure swings, and surges of systemic blood pressure and 
sleep fragmentation resulting from autonomic arousal (Kirkness, Krishnan, Patil, & Schneider, 
2006; Mbata & Chukwuka, 2011). In contrast, individuals with simple snoring may exhibit 
adequate compensatory neural responses to upper airway collapsibility, preventing the brief full 
occlusion of the oropharynx that is a hallmark of the apneic episode (Liistro et al., 1991; Ayappa 
& Rapoport, 2003). Beyond differences in mechanical respiratory characteristics observed during 
inspiration in simple snorers and OSA patients, researchers have also found differences in 
respiratory flow patterns between the groups. Supraglottic pressure and airflow rate relationships 
differ between nonapneic heavy snorers and OSA patients (Liistro et al., 1991). In the OSA 
pattern, the inspiratory flow rate plateaus at very low levels during the failed inspiratory efforts 
associated with apneic obstruction. This triggers a compensatory autonomic surge, causing the 
pharyngeal airway to open with a concurrent snore. Conversely, snoring in non-apneic heavy 
snorers is preceded by a decrease in pharyngeal airway diameter, resulting in a snore 
accompanying the next inspiration. 
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 1.3 SNORING AND DISEASE RISK 
 
 
Research suggests associations among habitual snoring and cardiovascular and cerebrovascular 
disturbances. In cross-sectional epidemiological surveys, snoring in women has been associated 
with increased prevalence of systemic hypertension (Lugaresi, Cirignotta, Coccagna, & Piana, 
1975; Norton & Dunn, 1985) and heart disease (Norton & Dunn, 1985). Prospective studies have 
found that greater frequency of snoring conferred greater risk for coronary heart disease and 
stroke in women (Hu et al., 2000). Case-control studies have demonstrated that habitual snoring 
is also associated with greater risk for myocardial infarction (D’Alessandro et al., 1990) and 
ischemic cerebral infarction (Partinen & Palomaki, 1985; Palomaki, 1991; Neau et al., 1995). A 
survey of subjective snoring frequency in 1,222 Hispanic-American adults found that snoring 
was associated with myocardial infarction (odds ratio, 1.8) even after adjusting for confounding 
physiological factors (Schmidt-Nowara et al., 1990). More recently, loud snoring has been 
shown to independently predict the development of the metabolic syndrome, a cluster of risk 
factors linked with incident CV events (Troxel et al., 2010). 
These studies have significant limitations. Few studies accounted for either clinical 
diagnosis or clinically-significant symptoms of sleep apnea. The studies did adjust for body mass 
index (BMI), which is often considered a proxy for SDB due to the positive correlation between 
BMI and apnea-hypopnea index (AHI). However, a sizable percentage of individuals diagnosed 
with sleep apnea are within normal BMI range, suggesting that BMI alone does not fully 
represent sleep apnea diagnosis or symptomatology. In addition, much of the snoring data from 
these studies was provided through self-report, often in the form of a single question assessing 
the weekly frequency of habitual snoring. While it is possible that individuals with bed partners 
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 may be able to provide more accurate information, self-reported snoring frequency in all of the 
aforementioned studies was uncorroborated by bed partners.  
Recently, Lee and colleagues (2008) recruited a sample of 110 male and female non-
snorers and snorers, with a mean age of 58.2 ± 7.9 years, in order to investigate the cross-
sectional association between objectively-assessed snoring and carotid atherosclerosis plaque. 
None of the participants were hypoxic for more than 1% of their total sleep time, indicating that 
this sample was relatively free of SDB. All of the participants underwent a 
polysomnographically-recorded sleep night where snoring data was captured using a 
unidirectional microphone and quantified in visually scored “snore epochs” across the night. 
Atherosclerotic plaque (absence or presence) in both the carotid and femoral artery was detected 
by ultrasound. Heavy snoring was significantly associated with the presence of carotid 
atherosclerotic plaque, independently of nocturnal hypoxia and AHI, and was not found to be 
associated with femoral plaque. This was the first study to use ultrasound methodology to 
investigate whether the presence of carotid plaque was associated with objectively-scored 
snoring. 
 
 
 
 
1.4 THE INFLAMMATION-ENDOTHELIAL DYSFUNCTION MODEL OF 
SNORING-RELATED ATHEROGENESIS 
 
 
If one separates simple snoring from the OSA literature, removing the potent effects of hypoxia 
and sleep fragmentation on physiological variables, it becomes necessary to propose a model that 
can account for the relationship between independent snoring-induced vibration and 
atherosclerosis. We argue that snoring represents an independent risk factor due to repeated 
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 mechanical injury to pharyngeal and nearby structures. Drawing together disparate findings in 
the snoring literature, we proposed the inflammation-endothelial dysfunction model of snoring-
related atherogenesis (Figure 2).  
 
 
 
 
 
 
Figure 2. Inflammation-Endothelial Dysfunction Model of Snoring-Related Atherogenesis. 
 
 
  
(1) 
(2) 
(3) 
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 Snoring-induced vibrations result in oscillatory pressure waves (Hedner et al., 1994), 
which travel through the nearby carotid artery bifurcation, triggering both arterial endothelial 
damage and an inflammatory response (cf. Almendros et al., 2007; Curry et al., 2002; Cho et al., 
2011; Amatoury et al., 2006). The bidirectional feed-forward relationship between inflammation 
and endothelial dysfunction may be maintained by habitual nocturnal snoring, contributing to 
carotid atherogenesis. Increased inflammation from the snoring vibrations results in higher levels 
of localized pro-inflammatory cytokines, which modulate the production of endothelial nitric 
oxide synthase (eNOS). eNOS produces nitric oxide (NO), the primary endothelium-released 
vasodilator and antithrombotic factor associated with maintaining vascular tone and endothelial 
functioning (Verma & Anderson, 2002; Yan et al., 2008). Down-regulated NO production or 
release results in increased vasoconstriction and decreased vasodilation, leading to endothelial 
dysfunction and an increase in the production of cytokines and other inflammatory factors, such 
as CRP. This cycle may be perpetuated by chronic snoring, eventually leading to the 
development and maintenance of atherosclerosis and potential plaque rupture. Further, this cycle 
may be independent of SDB, suggesting that simple snoring is an independent risk factor for 
CVD. 
 
 
1.4.1 Vibration and Endothelial Dysfunction 
 
 
As stated earlier, snoring occurs in the upper airway as pharyngeal constrictions result in 
vibrations of the soft palate, pharyngeal walls, epiglottis, and tongue (Ayappa & Rapoport, 2003; 
Liistro et al., 1991). Twenty years ago, Hedner and colleagues (1994) proposed that oscillatory 
pressure waves generated by snoring vibrations can be transmitted through the cellular medium 
to surrounding tissues, including the carotid artery. The bifurcation of the carotid artery lies 
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 proximal to the hypopharynx, just below the oropharynx where the snoring pressure waves 
originate (Figure 3).  
 
 
 
 
 
 
Figure 3. Location of the Human Hypopharynx Proximal to the Carotid Artery Bifurcation. 
 
 
 
Recent studies in rabbit models have demonstrated that induced snoring in the pharyngeal 
region increases the tissue pressure not only at the carotid artery bifurcation, but also within the 
carotid sinus lumen, indicating that energy is successfully transmitted from the pharyngeal 
tissues across the carotid artery wall (Amatoury et al., 2006). In a similar study of induced 
snoring in rabbits, both frequency and amplitude of the oscillatory pressure wave generated in 
the pharyngeal structures resulted in detectable pressure oscillations in the carotid artery 
bifurcation and sinus lumen (Howitt et al., 2007). These data support the proposal that snoring 
induces oscillatory pressure waves that are transmitted to nearby vascular structures. Further, 
they provide support for a pathway between the objective snoring and atherosclerosis 
relationship reported by Lee and colleagues (2008). 
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  Outside of the limited published snoring literature, other studies of vibration in humans 
and animals have been associated with endothelial dysfunction. For example, vibration-induced 
Raynaud’s phenomenon (VRP) is associated with long-term exposure to hand-transmitted 
vibration at work, and is characterized by digital ischemic attacks and motor and neural 
symptoms in the hands and arms (Stoyneva, Lyapina, Tzvetkov, & Vodenicharov, 2003). 
Endothelial damage and dysregulation have been detected in individuals with VRP, supported by 
elevated plasma levels of thrombomodulin and endothelin-1, the latter of which inhibits the 
effects of NO (Bourque, Davidge, & Adams, 2011). Endothelin-1 and NO are counterparts in 
maintaining vascular function, and imbalance in these factors is implicated in the progression of 
vascular disease (Khimji & Rockey, 2010). Workers with VRP also exhibit deficient peripheral 
circulation resulting from vasoconstriction, a conceptual analogue to coronary arterial 
vasoconstriction resulting from chronic snore-induced vibration (Herrick, 2005). 
Mechanistically, vibration injury in a rat tail model has shown that endothelial cells 
showed signs of damage after a single 4-hour bout of vibration, and vibration for 9 days at a 
level of 60 Hz for four hours a day resulted in thinning and death of endothelial cells (Curry et 
al., 2002). Vibration-induced vacuoles following one day of vibration are morphologically 
similar to those formed under norepinephrine application, suggesting that vibration induces 
vasoconstriction. Cho et al. (2011) have demonstrated that vibrated carotid arteries in rabbits 
show signs of endothelial dysfunction as measured by decreased vasorelaxation to acetylcholine. 
In order to isolate primary snoring-induced vibration as the sole independent variable, the 
authors utilized a rigorous method to prevent features associated with sleep apnea, including 
hypoxemia, large intra-pleural variation, and blood pressure changes. The results of these studies 
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 cumulatively support the theory that vibration alone can cause endothelial damage, resulting in 
endothelial dysfunction. 
 
 
1.4.2 Vibration and Inflammation 
 
 
Vibration has been demonstrated to trigger inflammation and overexpression of pro-
inflammatory cytokines.  A sample of annulated rats was subjected to 3 hours of a 1-second 
upper airway vibration followed by 3-second no vibration pattern, which the authors 
conceptualized as analogous to the human snoring pattern of heavy snorers (Almendros et al., 
2007). Gene expression analysis found mRNA overexpression of tumor necrosis factor-α (TNF-
α) and macrophage inflammatory protein-2 (MIP-2) in the soft palates of the rats subjected to 
vibration compared to control cannulated rats who did not receive the vibration. A cell model of 
snoring-induced airway inflammation found that human bronchial epithelial cell cultures 
subjected to vibration for 12 to 24 hours exhibited significantly increased concentrations of the 
chemokine interleukin-8 (IL-8; Puig et al., 2005). It is currently unknown whether vibration 
results in the overexpression of other inflammatory markers.  
 
 
1.4.3 Bidirectional Relationship between Inflammation and Endothelial Dysfunction 
 
 
The results of these vibration studies provide support for the inflammation-endothelial 
dysfunction model of atherogenesis. TNF- α and IL-8 are both implicated in the maintenance of 
endothelial functioning, and elevations in both are associated with adverse cardiovascular 
outcomes. The primary function of IL-8, a chemokine synthesized by macrophages and 
endothelial cells, is to recruit and activate neutrophils at the site of inflammation (Hammond et 
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 al., 1995). In a prospective case-control population study, individuals in whom coronary artery 
disease developed had elevated baseline IL-8 concentrations, and participants in the highest IL-8 
quartile were at the greatest risk for future CAD (Boekholdt et al., 2004). Similarly, TNF-α has 
been shown to be related to endothelial functioning. TNF-α downregulates the expression of 
endothelial nitric oxide synthase (eNOS; Yan et al., 2008). eNOS produces nitric oxide, which 
regulates vascular function and maintains endothelial functioning. Increases in TNF-α are, 
therefore, associated with impaired endothelial functioning. Importantly, TNF-α-mediated 
inhibition of eNOS has been associated with atherosclerosis and heart failure (Picchi et al., 2006; 
Agnoletti et al., 1999). TNF-α also stimulates the production of IL-8 (Azevedo et al., 2013), 
suggesting that vibration-induced overexpression of these two factors contributes to a feed-
forward inflammatory response that results in endothelial dysfunction. 
 
 
1.4.4 Role of C-reactive Protein in Inflammation, Endothelial Dysfunction, and CVD 
 
 
The production of IL-8 and TNF-α can be further stimulated by C-reactive protein (CRP) 
(Galve-de Rochemonteix et al., 1993; Xie et al., 2005). CRP is an inflammatory agent involved 
in the induction of pro-coagulant activity in the endothelium and in recruiting inflammatory cells 
into atherosclerotic plaques (Apostolopoulus, Davenport, & Tipping, 1996). Plasma CRP has 
been shown to be relatively stable in a given individual over 24 hours (Libby, 2002). To date, no 
study has directly tested whether vibration results in increased production of CRP, although this 
is a plausible mechanism. The observed associations between vibration and increased IL-8 and 
TNF-α may be mediated by increased levels of CRP, which further contributes to the formation 
of atherosclerotic plaques. In turn, macrophages from atherosclerotic plaques demonstrate an 
enhanced capacity to produce IL-8 (Apostolopoulus, Davenport, & Tipping, 1996). The 
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 inflammation-endothelial dysfunction model of atherogenesis is therefore a feed-forward 
bidirectional relationship driven by vibration. 
Studies in animal and human models have suggested a pro-atherogenic role of C-reactive 
protein (CRP) via the inflammation and endothelial dysfunction pathways. Exposure of the 
endothelium to CRP induces pro-coagulant activity and the expression of cell surface adhesion 
molecules, which impair vascular relaxation. An in vivo mouse model found that human CRP 
transgene expression resulted in accelerated aortic atherosclerosis (Paul et al., 2004). In humans, 
elevated CRP levels have been associated with blunted systemic endothelial vasodilator function, 
implicating CRP in endothelial dysfunction and long-term coronary artery disease (Fichtlscherer 
et al., 2000). One human study using an invasive measure of endothelial functioning found that 
chronic low-grade inflammation, characterized by elevated CRP levels, was significantly related 
to decreased endothelial NO synthesis, providing convincing support for the role of CRP in the 
development of hypertension and atherogenesis (Cleland et al., 2000).  
In the human literature, CRP has been shown to be a remarkably robust biomarker for 
CVD risk. A meta-analysis of 7 prospective studies found that a 1.4 mg/L increase in circulating 
CRP above the upper limit clinical threshold of 1.0 mg/L (or 2.4 mg/L total) was associated with 
a combined risk ratio of developing CHD of 1.7 (95% CI=1.4-2.1; Danesh et al., 1998). CRP 
levels around the upper clinical limit of 1.0 mg/L have variously been associated with a 2- to 3-
fold increased risk of adverse cardiovascular outcomes, including myocardial infarction and 
ischemic stroke (Ridker et al., 1998), peripheral vascular disease (Ridker, 1998), and coronary 
heart disease (Kuller et al., 1996; Koenig et al., 1999). Due to CRP’s demonstrated role in both 
inflammation and endothelial functioning, it represents an opportune biomarker for investigation 
in the present study.  
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2.0 STUDY AIMS 
 
 
 
 
While each of the aforementioned studies addresses a component of the proposed simple 
snoring-induced atherogenesis model, research is needed to draw together these disparate 
findings in order to test and refine the conceptual physiological model. As a first step, research is 
needed in humans to investigate how snoring vibration affects inflammatory markers. We have 
chosen to look at CRP on the basis of its predictive value for CVD risk in humans and its role in 
endothelial dysfunction, as established in the animal and cell model literature. 
This is the first study to investigate the relationship between objective snoring and a 
cardiovascular disease biomarker in midlife women. The overall purpose of this study was to 
investigate whether snoring, as measured objectively by vibrations at the surface of human 
pharyngeal structures, is associated with elevations in circulating levels CRP. Specifically, the 
study aimed to investigate whether snoring and CRP were associated in a positive dose-response 
manner and whether this relationship was specifically observed in simple snorers, defined by the 
absence of sleep apnea (AHI ≥ 5). Further, given the hypothesized role of snoring-induced 
atherogenesis in postmenopausal women, we sought to investigate whether the snoring and CRP 
relationship differed as a function of menopausal status. Objective snoring data were derived and 
scored from existing polysomnographic (PSG) sleep studies, which included a microphone 
designed to detect snoring. Subjective snoring data were derived from participants’ report of 
frequency of loud snoring across the week. Circulating CRP levels were derived from blood 
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 samples assayed using a high sensitivity C-reactive protein (CRP) assay at two blood draw time-
points temporally closest to the sleep recording night (Ockene et al., 2001). We hypothesized 
that simple snorers and individuals with sleep disordered breathing would have higher levels of 
CRP compared to non-snorers. Given that postmenopausal women are at the greatest risk for 
CVD morbidity and mortality, we further predicted that the association between objective 
snoring and CRP would be strongest in our group of postmenopausal women. 
Because little is known about the correlates of snoring in midlife women, we further 
sought to characterize our sample on the basis of their objective and subjective snoring values. 
Post hoc characterization based on the presence or absence of both sleep disordered breathing 
and objective snoring enabled us to create three groups of women: absent or mild snorers 
(AHI<5), simple snorers (AHI<5), and sleep disordered breathers (AHI≥5). Based on known 
associations between OSA, obesity, and CVD risk, we predicted that women in the sleep 
disordered breathing group would have the poorest health profiles and greatest number of CVD 
risk factors, such as high blood pressure and BMI. Our conceptual model suggests that simple 
snorers would also display poor health profiles and greater CVD risk than absent or mild snorers. 
On the basis of previous research showing that loud snoring is associated with increased 
metabolic risk (Troxel et al., 2010), we further predicted that simple snorers would have poorer 
metabolic profiles. Finally, given established differences in self-reported snoring prevalence 
between Caucasian and African American women and craniofacial differences in morphology 
(Lee, Ramirez, & Will, 1997; Redline et al., 1997), we predicted subjective and objective snoring 
would be more prevalent in African American compared to Caucasian participants. 
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3.0 METHODS 
 
 
 
 
3.1 PARTICIPANTS 
 
 
The SWAN Sleep Study is a cross-sectional study of sleep in a multi-ethnic cohort of midlife 
women. It is an ancillary study of the Study of Women’s Health Across the Nation (SWAN), a 
longitudinal, multi-site study of the psychological, behavioral, social, and physiological 
correlates and consequences of the menopausal transition. The SWAN Sleep Study cohort 
included 368 Caucasian, African American, and Chinese participants studied at four sites: 
Pittsburgh, PA; Chicago, IL; Detroit, MI; and Oakland, CA. Each site recruited Caucasian 
participants as well as one minority group: African American participants were recruited from 
the Pittsburgh, Chicago, and Detroit sites, and all Chinese participants were recruited from the 
Oakland site. To maintain sufficient power to examine racial differences, our study included only 
African American and Caucasian participants whose closest SWAN Core follow-up visit 
occurred within a window of 365 days either before or after the SWAN Sleep Study date 
(Caucasians: n=140, mean age = 51.29 ± 2.10 years; African Americans: n=116, mean age = 
50.94 ± 2.13 years). 
Participants were excluded from participation in the SWAN Sleep Study for: current 
menopausal hormone replacement therapy (HRT) use; current oral corticosteroid use; current 
chemotherapy or radiation; regular shiftwork; and noncompliance with core SWAN procedures. 
Participants with missing snore channel data or who reported the use of interventions to modify 
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 or reduce snoring [e.g. continuous positive airway pressure (cPAP)] were excluded from 
analyses. Informed consent was obtained at each participating institution. Participants were 
compensated for their participation. For the purposes of the present study, each participant’s 
CRP data were drawn from the closest annual SWAN Core assessment that fell within one year 
of their SWAN Sleep Study visit date (range: 362 days prior to sleep night to 364 days post-sleep 
night). For those women whose two closest annual SWAN Core assessments fell within one year 
on either side of their sleep study visit date (n=138), an average of both CRP values were used to 
improve measure reliability (Ockene et al., 2001). This measure appears fairly stable, given the 
high degree of correlation between the two CRP values for these participants (r=0.517, p=.001).  
 
 
 
 
3.2 DEMOGRAPHIC MEASURES 
 
 
Sociodemographics were assessed through participant self-report at the SWAN Core 
baseline assessment and included age, racial/ethnic identification (Black or African American, 
non-Hispanic White, or Chinese or Chinese American), highest educational attainment, total 
family income, and employment status. Menstrual bleeding patterns were used to characterize 
menopausal status (premenopause/early perimenopause, late perimenopause, and 
postmenopause/surgical menopause) according to World Health Organization criteria (World 
Health Organization, 1996). 
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3.3 PHYSIOLOGICAL MEASURES 
 
 
Given the established relationship between adiposity and tissue mass and both snoring 
and SDB, key anthropometric data were collected (Kaditis et al., 2008; Nieto et al., 2000; Olson 
et al., 1995). Neck circumference was measured in centimeters at the cricothyroid cartilage. The 
measurement was taken by the sleep study technician on the first night of in-home PSG. Waist-
hip ratio was calculated from measurements taken at the closest preceding SWAN Core visit. 
Waist circumference was measured at the natural waist or narrowest part of the torso, and hip 
circumference was measured at the widest part of the hip. Body mass index (BMI) was measured 
as weight in kilograms divided by height in meters squared, and measurements were taken at the 
baseline SWAN Sleep study assessment using calibrated scales. 
Blood and vascular physiological data were collected at the closest SWAN Core visit 
preceding the SWAN Sleep study. Blood pressure readings were measured according to a 
standardized protocol, with readings taken on the right arm and with the participant seated with 
feet flat on the floor for at least 5 minutes before measurement. Participants had not smoked or 
consumed caffeine within 30 minutes of measurement. Two sequential blood pressure readings 
were averaged for systolic and diastolic blood pressure. Phlebotomy was scheduled to coincide 
with the early follicular phase (days 2-7) of the participant’s menstrual cycle (in 87.6% of 
women) and was performed on the morning following an overnight fast (in 96.2% of women). 
Total cholesterol and triglyceride levels were analyzed using previously described enzymatic 
methods (Steiner et al., 1981) on a Hitachi 747 analyzer (Boehringer Mannheim Diagnostics, 
Indianapolis, Indiana). High-density lipoprotein cholesterol (HDL-C) was isolated using heparin-
2M manganese chloride (Warnick & Albers, 1978). Glucose levels were measured using a 
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 hexokinase-coupled reaction (Boehringer Mannheim Diagnostics, Indianapolis, Indiana). Insulin 
level was measured using solid-phase radioimmunoassay (DPC Coat-A-Count Insulin RIA; 
Diagnostic Products, Los Angeles, CA). 
Overall health and physician-reported medical diagnoses were assessed at the SWAN 
Core baseline interview. Participants provided dichotomous (yes/no) responses to medical 
diagnosis of anemia, Type II diabetes, high blood pressure, high cholesterol, migraine, stroke, 
osteoarthritis, over- or under-active thyroid, heart attack, angina, osteoporosis, or cancer. All 
positive responses were summed for each participant to create a sum of physician-diagnosed 
health conditions. 
 
 
 
 
3.4 HEALTH BEHAVIOR MEASURES 
 
 
Mean daily cigarette, caffeine, and alcohol consumption were drawn from the participants’ 
responses on the Pittsburgh Sleep Diary (Monk, 1994), which was administered concurrently 
with the PSG-assessed sleep nights. Sleep medication usage, exercise, and vasomotor symptoms 
were calculated as the percent any was reported on the Pittsburgh Sleep Diary across all study 
days. Passive smoke exposure category was derived from total person hours of exposure to 
passive smoke in the home, at work, or other in one week, as previously described (Coghlin, 
Hammond, & Gann, 1989). 
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 3.5 PSYCHOLOGICAL MEASURES 
 
 
A number of psychological variables were assessed in the study. Bodily pain (SF-36 Pain Index) 
and quality of life (0=worst to 10=best) were assessed at the SWAN Core baseline interview. 
Social support (0=least to 16=most) and financial strain (0=not hard at all, 1=somewhat/very 
hard) were assessed by interview at the closest SWAN Core visit preceding the SWAN Sleep 
study. Scores on the 16-item Inventory of Depressive Symptomatology (IDS), the 4-item 
Perceived Stress Scale (PSS), and the 10-item Spielberger State-Trait Anxiety Inventory (STAI) 
were averaged across administrations during the SWAN Sleep Study.  
 
 
 
 
3.6 PSG-ASSESSED AND SELF-REPORTED SLEEP MEASURES 
 
 
Polysomnographic studies were conducted over three consecutive nights using Vitaport-3 
(TEMEC VP3) ambulatory monitors. Sleep study staff visited the participant’s home on the 
evening of each sleep study night to apply electrodes and calibrate the channels. Upon arising in 
the morning, participants turned off the recorders and removed their equipment. Quality 
assurance assessments, processing, and scoring of all sleep records were performed at the 
University of Pittsburgh Neuroscience-Clinical and Translational Research Center (N-CTRC). 
The raw snore channel was archived for later scoring. 
Polysomnography signals included bilateral central referential EEG channels (C3 and C4, 
referenced to A1 tied to A2), electrooculogram (EOG), submentalis electromyogram (EMG), and 
electrocardiogram (EKG), nasal pressure cannula, oral-nasal thermistors, fingertip oximeter, and 
abdominal and thoracic respiratory effort, as measured by inductance plethysmography. Nasal 
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 pressure was used to measure airflow for scoring apneas and hypopneas, and the apnea/hypopnea 
index (AHI) was scored according to standard guidelines (ASDA, 1992). 
Two measures of self-reported sleep were assessed in the study. The 8-item Epworth 
Sleepiness Scale (ESS) was administered on the last day of the SWAN Sleep Study. Scores on 
the Pittsburgh Sleep Quality Index (Buysse et al., 1989) were averaged across administrations on 
the 4th and last days of the study. 
 
 
 
 
3.7 OBJECTIVE SNORING MEASURES 
 
 
The snore signal was collected using a specialized microphone, which translated snoring-induced 
vibrations into an electrical signal that oscillated in proportion to air pressure variations. The raw 
signal, collected in millivolts (mV), captured both duration (length of snoring event) and 
amplitude (strength of vibration pressure). Previous studies have found no statistically significant 
change in AHI or SDB across PSG nights, indicating little night-to-night variability in breathing-
related channels (Davidson, Gerhman, & Ferreyra, 2003; Stepnowsky, Orr, & Davidson, 2004; 
Chediak et al., 1996). These data suggest that one night of PSG-recorded sleep was sufficiently 
representative of snoring activity. 
Snore events were visually scored following a scoring paradigm established a priori 
under the aegis of a respiratory sleep medicine expert, Dr. Tom Rice, and a PSG signal analyst 
expert, David Cashmere. The visual scoring paradigm included the following criteria, all of 
which had to be met for a positive snore event: 1) duration of ≥0.4 seconds; 2) ≥300% amplitude 
change from baseline mV signal; 3) occurring only once per breath, as established using 
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 respiratory PSG signals; 4) occurring during inspiration and/or expiration; 5) not occurring 
during epochs scored as wake or at the juncture of a transition to or from wake.  
 
 
3.7.1 Rationale for Snoring Scoring Paradigm 
 
 
The scoring methodology was adapted from that used by Lee et al. (2008) for uncalibrated 
signals. The duration parameter represented a sufficient period for snoring accompanying 
inspiration or expiration and was deemed sufficiently long to eliminate artifacts of sleep, such as 
sighing, rustling, and snorts (T. B. Rice, personal communication, June, 2012). The amplitude 
parameter was established to eliminate non-snoring sleep artifacts, including labored breathing 
and non-snoring sounds, such as murmurs or mumbles. Because the snore channel was not 
calibrated to a standardized baseline voltage before recording, the baseline signal was established 
independently for each individual using the bio-calibrations performed at the beginning of the 
night’s recording period. Since snoring occurs with either the inspiration or expiration phase, and 
occasionally throughout both phases, only events occurring in one of these phases were counted 
as snore events, pursuant to convention (e.g. Schwartz, Salome, Ingmundon, & Rugh, 1996; 
Hoffstein, Mateika, & Mateika, 1991). Snoring events occurring during both the inspiration and 
expiration phase were scored as a single event. Only NREM and REM sleep epochs were scored. 
Putative events occurring immediately on or before sleep-to-wake transitions were excluded as 
candidate events and not scored, as they may have been artifacts of wake. To ensure that these 
parameters were satisfied, the snore channel was visually compared to the corresponding 
respiration (thoracic, abdominal effort), oxymetry, submentalis EMG, and EEG (C4) channels. 
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 3.7.2 Training and Reliability of Scorers 
 
 
In addition to the paradigm developer, who was considered the Ground Truth scorer, we trained 
5 raters on the snoring scoring paradigm. Twelve reliability files were used to evaluate the 
reliability of scorers. These records were identified a priori on the basis of four primary 
characteristics associated with snoring: race (African American or Caucasian), BMI (≥30 or 
<30), presence of sleep disordered breathing (AHI <5 or ≥5), and self-reported snoring (Never, 
Infrequent, or Frequent). Permutations of these characteristics were selected and may be seen in 
Table 1. These reliability files were selected to train scorers on varying degrees of PSG channel 
complexity and assess inter-rater reliability along a spectrum of scoring difficulty. One reliability 
file was excluded from scoring and reliability analysis due to technical complications. 
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 Table 1. Participant Characteristics for Selected Reliability File Records. 
 
 
 Race BMI AHI 
Self-Reported 
Snoring 
Frequency 
511070 White Normal Non-SDB Never 
511037 Black Normal SDB Never 
513052 Black Overweight Non-SDB Never 
511009 White Overweight SDB Never 
513031 Black Normal Non-SDB Infrequent 
517043 White Normal SDB Infrequent 
517072 White Overweight Non-SDB Infrequent 
511012 Black Overweight SDB Infrequent 
513079 Black Normal Non-SDB Frequent 
514061 White Normal SDB Frequent 
511061 Black Overweight Non-SDB Frequent 
513094 White Overweight SDB Frequent 
Totals White = 6 
Black = 6 
Normal = 6 
Overweight = 6 
Non-SDB = 6 
SDB = 6 
Never = 4 
Infrequent = 4 
Frequent = 4 
Notes: BMI categorization: Normal <30; Overweight ≥30. AHI categorization:  
Non-SDB <5; SDB ≥5. Subjective snoring categorization based on responses to PSSQ loud 
snoring question. 
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 Training was done in two waves: three scorers were trained in January-February 2013 
and two scorers were trained in September-October 2013. The training protocol lasted 
approximately 20-30 hours in total and followed a sequential process: a) group overview of the 
paradigm parameters and rationale for each parameter; b) group training in the use of Harmonie 
software (Stellate System, Montréal, Québec, Canada); c) group training in identification of 
snoring events per paradigm criteria; d) blind group identification of putative events, with 
rationale and discussion; and e) individual scoring of the reliability files and exportation  of 
events to the Ground Truth scorer. All components of the training process were led by the 
paradigm developer. 
Inter-rater reliability was calculated using the F-measure (Goutte & Gaussier, 2005). 
Each snore event was given a binary label l representing the correctness of that identification per 
the paradigm criteria. Each trained scorer assigned a binary label z indicating whether he or she 
believed the event to be a snore or not. The following table summarizes the possible outcomes: 
  Snore Label (Ground Truth)  
l  
  + - 
Snore 
Assignment 
(Trainee) 
z 
+ True Positive (TP) 
False Positive 
(FP) 
- False Negative (FN) 
True Negative 
(TN) 
 
From these counts, precision (P), recall (R), and F-score were calculated as follows: 
𝑃𝑃 = 𝑇𝑇𝑃𝑃
𝑇𝑇𝑃𝑃 + 𝐹𝐹𝑃𝑃               𝑅𝑅 = 𝑇𝑇𝑃𝑃𝑇𝑇𝑃𝑃 + 𝐹𝐹𝐹𝐹               𝐹𝐹 = 2(𝑃𝑃 ∗ 𝑅𝑅)(𝑃𝑃 + 𝑅𝑅)  
The P, R, and F-score statistics were calculated for each of the final reliability files (n=11). Table 
2 shows that overall reliability was high, with an average F-score of .84. The observed low and 
non-existent (designated not a number, or “Nan”) F-scores for 511070 and 513079, respectively, 
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 are due to the small number of scored snoring events in these records (511070 had 2 events; 
513079 had 0 events). Exclusion of these records yields an overall F-score of .89. Graphical 
representations of F-score comparisons for all reliability files where snoring was present (n=10) 
are included in Appendix A. For robustness, permutations of the F-measure were conducted 
using each trained scorer as the Ground Truth, for a total of 66 reliability calculations and overall 
F-scores of .80 (all records) and .89 (excluding non-snorers; see Appendix B). The results of 
these analyses suggest that inter-rater reliability was acceptable overall. 
 
 
 
Table 2. Reliability File F-scores Compared to Gold-Standard Ground Truth. 
 
 
 511037 
5130
31 
5130
52 
5110
09 
5110
06 
5110
70 
5130
79 
5130
94 
5140
61 
5170
43 
5170
72 
Expert 
1 
.84 .93 .89 .88 .85 .36 Nan .87 .90 .96 .94 
Expert 
2 
.84 .95 .78 .90 .84 .40 Nan .84 .87 .95 .93 
Expert 
4 
.85 .96 .82 .89 .80 Nan Nan .85 .96 .96 .93 
Expert 
5 
.80 .94 .76 .82 .92 .22 Nan .92 .94 .94 .93 
Expert 
6 
.83 .91 .78 .88 .88 .40 Nan .92 .91 .94 .92 
Notes: Nan = not a number. 
 
 
 
3.7.3 Objective Snoring Group Classification 
 
 
Each 20-second sleep epoch that contained 2 or more snore events was scored as a snore epoch 
(cf. Lee et al., 2008). The average respiratory rate in a healthy adult at rest is 12-18 breaths per 
minute (Tortora & Anagnostakos, 1990) or 4-6 breaths per 20-second epoch. Two or more snore 
events, each occurring with one breath, therefore represents one-third to one-half of the sleep 
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 epoch and is of sufficient duration to denote a “snore epoch” (T. B. Rice, personal 
communication, June, 2012). The independent variable “snoring index” (“SI”) was calculated as 
a continuous variable and represented the percentage of the total number of snoring epochs 
divided by the number of total sleep epochs.  
Participants were categorized into three orthogonal objective snoring groups pursuant to 
criteria established by Lee et al. (2008):  Individuals with a snoring index (SI) < 25% and AHI < 
5 were classified as “Absent” (n=31); individuals with an SI ≥ 25% and AHI < 5 were classified 
as “Simple Snorers” (n=82); and individuals with an AHI ≥ 5 were classified as “Sleep 
Disordered Breathing” (n=128).  
 
 
3.7.4 Subjective Snoring Group Classification 
 
 
Four subjective snoring groups were established using participants’ responses to the following 
question on the Pittsburgh Sleep Symptom Questionnaire (PSSQ): “During the past month, how 
many nights have you had, or been told you had, loud snoring?” Responses included “Never”, 
“Do not know”, “Rarely (less than once per week)”, “Sometimes (1-2 times per week)”, 
“Frequently (3-4 times per week)”, and “Always (5-7 times per week)”. We used the established 
criteria for detecting clinically significant sleep disturbances as defined by symptoms occurring 3 
or more times per week (Okun et al., 2009). Participants who endorsed loud snoring “Rarely” or 
“Sometimes” were classified as “Infrequent” (n=54). Participants who endorsed loud snoring 
“Frequently” or “Always” were classified as “Frequent” (n=51). Respondents endorsing “Never” 
were classified as “Never” (n=119). Respondents endorsing not knowing their snoring frequency 
were classified as “Don’t Know” (n=76). 
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3.8 HIGH SENSITIVITY C-REACTIVE PROTEIN 
 
 
A fasting blood draw was collected annually during SWAN core visits. The majority of the blood 
draws were scheduled to coincide with the early follicular phase of the participant’s menstrual 
cycle and prior to 10:00 a.m. CRP is robust to diurnal variation (Meier-Ewert, 2001), suggesting 
that any time-of-day variation may not have affected the CRP values in this sample. All samples 
were maintained at 4°C until separated, frozen at -80°C, and shipped on dry ice to the central 
laboratory (Medical Research Laboratories, Highland Heights, KY, USA). CRP was measured 
using an ultra-sensitive rate of immunonephelometry (Dade-Behring, Marburg, Germany). The 
CRP level taken at the SWAN core visits closest to the SWAN Sleep study date (within 365 
days) was used as our outcome variable. For women with CRP measured at two time points 
within 365 days of their sleep study night (n=138), the average of these values was used. The 
rationale for this inclusion is that two time points would provide a more stable and reliable 
measure of CRP. Research suggests that CRP > 10 mg/L indicates acute inflammation (Ridker, 
2003) and may not be representative of average baseline level of inflammation. Because of this, 
analyses were conducted with the full sample first, and sensitivity analyses were then conducted 
with individuals with CRP values > 10 mg/L (n=33) removed. 
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4.0 PRIMARY DATA ANALYSES 
 
 
 
 
4.1 DESCRIPTIVE STATISTICS 
 
 
Continuous predictor and dependent variables were tested for normality of distribution. CRP was 
normalized using natural log transformation, and AHI was normalized using square root 
transformation. Descriptive statistics [mean (s.d.) or n (%)] were first run on the full sample for 
the 7 variable classes identified in our measures: 1) demographic, 2) physiological, 3) health 
behavior, 4) psychological, 5) PSG-assessed sleep, 6) self-reported sleep, and 7) snoring 
variables.  
 
 
 
 
4.2 CORRELATES OF OBJECTIVE AND SUBJECTIVE SNORING 
 
 
Few studies have included both objective and subjective measures of snoring, so both measures 
were used to characterize our sample of midlife women. We examined snoring group for each of 
the 7 classes of variables. One-way analysis of variance (ANOVA) or chi-square tests were 
conducted to test for overall differences between the 3 objective snoring groups (Absent, Simple 
Snorers, SDB). Identical comparisons were conducted to test for overall differences between the 
4 subjective snoring groups (Never, Don’t Know, Infrequent, Frequent). For analyses with 
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 significant omnibus F-statistics (p<0.05), post-hoc Tukey’s least significant differences (LSD) 
tests were run to identify the nature of the group differences. 
 
 
 
 
4.3 MAIN MODELS 
 
 
Candidate covariates selected a priori for inclusion in analyses were age, race, absolute value of 
days between blood draw and sleep study night, use of medications that affect sleep, cigarette 
and alcohol use, BMI, and menopausal status. All covariates were selected on the basis of 
established associations with sleep disordered breathing, snoring, or CRP. While total average 
cigarettes was initially selected as the smoking covariate, it was not significantly correlated with 
either SI or CRP. However, passive smoking exposure was significantly associated with both 
variables, and was included as a covariate. All covariates were found to be significantly 
correlated with either snoring index (SI) or CRP in bivariate correlation analyses (p<0.05).  
 We used three main models to test associations in the full sample between CRP and a) 
snoring index (SI), b) objective snoring group, and c) subjective snoring group. To determine 
whether SI was associated with CRP and whether this relationship was dependent on AHI, we 
used multiple linear regression to test the main effects of SI and AHI as well as the interaction 
between SI and AHI on CRP. SI and AHI were both centered prior to creating the interaction 
term. Covariates were entered into the model first, SI and AHI were entered next, and the SI by 
AHI interaction variable was added third. To conduct the sensitivity analysis, we ommitted all 
participants with CRP>10 mg/L before running the multiple linear regression model again. To 
evaluate differences in CRP levels between the three objective snoring groups (Absent, SS, and 
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 SDB) and between the four subjective snoring groups (Never, Don’t Know, Infrequent, 
Frequent), analysis of covariance (ANCOVA) was used. 
 Two sub-analyses were conducted to test exploratory hypotheses. First, given the 
hypothesized particular significance of snoring in postmenopausal women, we used multiple 
linear regression to test the main effect of SI, main effect of AHI, and SI by AHI interaction on 
CRP in postmenopausal women only (n=41). Second, given the higher prevalence of self-
reported snoring and SDB in African American women reported elsewhere (O’Connor et al., 
2003; Redline et al., 1997; Scharf et al., 2004; Ram et al., 2010), we used multiple linear 
regression to test whether race moderated the relationship between SI and CRP. Race was 
dummy coded with the Caucasian group as the referent group and African American as the 
comparison group. Covariates were entered into the model first, followed by SI and dummy-
coded race, then the SI by race interaction term. We then calculated and plotted simple 
regression equations for Caucasian and African American groups and tested whether the simple 
slopes were significantly different from zero and from each other.  
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5.0 RESULTS 
 
 
 
 
5.1 CORRELATES OF OBJECTIVE SNORING 
 
 
A total of 171 Caucasian and 138 African American women participated in the SWAN Sleep 
Study. Of these, 133 Caucasian and 108 African American participants (total: 241, mean age 
51.95 ± 2.22 years) had usable apnea screening night PSG data and comprise the objective 
snoring sample used in analyses. Table 3 summarizes sample characteristics as a function of 
objective snoring group category.  
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 Table 3. Characterization of Midlife Women by Objective Snoring Group Designation. 
 
 
 
Objective Snoring Group 
 
Absent (A) Simple Snorers (SS) 
Sleep Disordered 
Breathing (SDB) Total 
Post-Hoc 
Group 
Differences 
Overall 
p 
 
(n=31) (n=82) (n=128) (n=241) 
Demographic Variables Mean (S.D.) or n (%) Mean (S.D.) or n (%) Mean (S.D.) or n (%) Mean (S.D.) or n (%)     
Age (years) 51.49 (2.10) 51.61 (1.92) 52.28 (2.38) 51.95 (2.22)* SS < SDB 0.045 
Race 
     
n.s. 
Caucasian (%) 19 (14.3%) 43 (32.3%) 71 (53.4%) 133 
  African American (%) 12 (11.1%) 39 (36.1%) 57 (52.8%) 108 
  Menopausal Status 
     
n.s. 
Premenopause / Early 
        peri-menopause (%) 21 (67.7%) 58 (71.6%) 75 (58.6%) 154 (64.2%) 
  Late peri-menopause (%) 5 (16.1%) 16 (19.8%) 24 (18.8%) 45 (18.8%) 
  Postmenopause (%) 5 (16.1%) 7 (8.6%) 29 (22.7%) 41 (17.1%) 
  Hormone replacement therapy 
use (%) 4 (12.9%) 2 (2.5%) 7 (5.5%) 13 (5.4%) 
 
n.s. 
Employment status 
     
n.s. 
Not employed (%) 4 (12.9%) 19 (23.5%) 21 (16.4%) 44 (18.3%) 
  Any employment (%) 27 (87.1%) 62 (76.5%) 107 (83.6%) 196 (81.7%) 
  Education level 
     
n.s. 
HS degree/some college (%) 17 (54.8%) 40 (50.0%) 65 (52.0%) 122 (51.7%) 
  College/postgraduate degree 
(%) 14 (45.2%) 40 (50.0%) 60 (48.0%) 114 (48.3%) 
  Income 
     
n.s. 
< $10,000 (%) 0 (0%) 4 (4.9%) 6 (4.7%) 10 (4.2%) 
  $10,000 - 19,999 (%) 2 (6.5%) 3 (3.7%) 9 (7%) 14 (5.8%) 
  $20,000 - 34,999 (%) 3 (9.7%) 8 (9.9%) 15 (11.7%) 26 (10.8%) 
  $35,000 - 49,999 (%) 6 (19.4%) 15 (18.5%) 15 (11.7%) 36 (15%) 
  $50,000 - 74,999 (%) 3 (9.7%) 18 (22.2%) 31 (24.2%) 52 (21.7%) 
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Objective Snoring Group 
 
Absent (A) Simple Snorers (SS) 
Sleep Disordered 
Breathing (SDB) Total 
Post-Hoc 
Group 
Differences 
Overall 
p 
 
(n=31) (n=82) (n=128) (n=241) 
$75,000 - 99,999 (%) 5 (16.1%) 14 (17.3%) 20 (15.6%) 39 (16.2%) 
  $100,000 - 149,999 (%) 4 (12.9%) 10 (12.3%) 18 (14.1%) 32 (13.3%) 
  > $150,000 (%) 4 (12.9%) 2 (2.5%) 9 (7%) 15 (6.2%) 
  Physiological Variables 
      Body mass index (BMI) (kg/m2) 25.99 (3.25) 29.61 (5.93) 34.40 (8.51) 31.69 (7.82)** A < SS < SDB 0.0001 
Waist-to-hip ratio  0.795 (0.065) 0.828 (0.064) 0.849 (0.077) 0.835 (0.073)** A < SS < SDB 0.001 
Neck circumference (cm) 34.03 (2.48) 35.80 (2.71) 38.01 (4.08) 36.73 (3.76)** A < SS < SDB 0.0001 
Apnea-hypopnea index (AHI) 2.46 (1.31) 2.49 (1.51) 18.83 (1.55) 11.20 (15.21)** A & SS < SDB 0.0001 
Systolic blood pressure (mm/Hg) 111.97 (13.08) 119.70 (17.35) 123.70 (17.22) 
120.83 
(17.17)** A < SS & SDB 0.002 
Diastolic blood pressure 
(mm/Hg) 72.84 (8.11) 73.06 (9.71) 74.96 (11.31) 74.04 (10.43) 
 
n.s. 
Vasomotor symptomsΔ 39.63 (33.52) 29.70 (32.14) 33.65 (35.62) 33.10 (34.20) 
 
n.s. 
No. metabolic syndrome criteria 
met 0.77 (0.97) 1.56 (1.25) 2.11 (1.47) 1.76 (1.41)** A < SS < SDB 0.0001 
Meets criteria for metabolic 
syndrome diagnosis (%) 3 (11.5%) 20 (28.6%) 49 (45.0%) 72 (35.1%)** A < SDB* 0.002 
Biomarkers 
      Average CRP values (mg/dL) 1.89 (1.65) 3.96 (5.20) 6.94 (8.08) 5.25 (6.87)** A & SS < SDB 0.0001 
Glucose (mg/dL) 84.13 (6.57) 88.56 (15.20) 98.60 (35.69) 93.30 (28.09)** A & SS < SDB 0.006 
Insulin (ulU/mL) 9.55 (3.62) 13.22 (12.86) 17.87 (14.71) 15.29 (13.52)** A & SS < SDB 0.004 
Physician-Reported Diagnosis 
      Diabetes (%) 1 (3.2%) 3 (3.7%) 10 (7.8%) 14 (5.8%) 
 
n.s. 
High blood pressure (%) 6 (19.4%) 5 (6.2%) 36 (28.1%) 47 (19.6%)** SS < SDB 0.001 
High cholesterol (%) 9 (29.0%) 5 (6.3%) 25 (19.8%) 39 (16.5%)** 
A > SS;  
SS < SDB 0.005 
Stroke (%) 0 (0%) 0 (0%) 1 (0.8%) 1 (0.4%) 
 
n.s. 
Heart attack (%) 0 (0%) 2 (2.5%) 0 (0%) 2 (0.8%) 
 
n.s. 
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Objective Snoring Group 
 
Absent (A) Simple Snorers (SS) 
Sleep Disordered 
Breathing (SDB) Total 
Post-Hoc 
Group 
Differences 
Overall 
p 
 
(n=31) (n=82) (n=128) (n=241) 
Sum of all physician-reported 
health diagnoses (scale 0-10) 0.807 (1.05) 0.482 (0.084) 0.930 (1.102) 0.763 (1.03)** SS < SDB 0.008 
General health 
     
n.s. 
Excellent/very good/good (%) 27 (87.1%) 73 (90.1%) 109 (85.2%) 209 (87.1%) 
  Fair / poor (%) 4 (12.9%) 8 (9.9%) 19 (14.8%) 31 (12.9%) 
  Health Behavior Variables 
      ExerciseΔ 53.43 (30.62) 55.98 (31.17) 49.26 (35.18) 52.09 (33.30) 
 
n.s. 
Caffeineǂ 2.05 (1.60) 1.48 (1.35) 1.58 (1.29) 1.61 (1.36) 
 
n.s. 
Alcoholǂ 0.49 (0.62) 0.38 (0.61) 0.22 (0.43) 0.31 (0.53)* A & SS > SDB 0.016 
Cigarettesǂ 0.46 (1.72) 0.92 (2.88) 1.09 (3.18) 0.95 (2.92) 
 
n.s. 
Sleep medication usageΔ 39.26 (49.09) 23.51 (41.41) 23.05 (40.54) 25.32 (42.19) 
 
n.s. 
Passive smoking exposure 
     
n.s. 
0 person-hours (%) 64.50% 37.20% 48.00% 46.60% 
  1-4 person-hours (%) 25.80% 33.30% 29.60% 30.30% 
  >5 person-hours (%) 9.70% 29.50% 22.40% 23.10% 
  Psychological Variables 
      IDS 4.62 (2.58) 4.53 (2.74) 5.41 (3.17) 5.01 (2.98) 
 
n.s. 
IDS no sleep variables 2.52 (2.29) 2.54 (2.54) 3.32 (2.96) 2.96 (2.76) 
 
n.s. 
Perceived Stress Scale 3.66 (2.66) 3.64 (2.39) 4.20 (2.85) 3.94 (2.68) 
 
n.s. 
State/Trait Anxiety Inventory 15.70 (4.95) 14.81 (3.99) 15.94 (2.93) 15.53 (4.65) 
 
n.s. 
Social support scale (scale 0-16) 13.06 (2.95) 13.07 (3.17) 13.27 (2.81) 13.18 (2.94) 
 
n.s. 
Bodily pain scale 72.10 (17.54) 72.19 (19.68) 67.77 (22.12) 69.82 (20.81) 
 
n.s. 
Quality of life scale (scale 0-10) 7.74 (1.75) 7.68 (1.38) 7.66 (1.65) 7.68 (1.57) 
 
n.s. 
Difficulty paying for basics 
     
n.s. 
Not hard at all (%) 21 (67.7%) 53 (66.2%) 90 (70.3%) 164 (68.6%) 
  Somewhat / very hard (%) 10 (32.3%) 27 (33.8%) 38 (29.7%) 75 (31.4%) 
  PSG-assessed Sleep Variables 
      Sleep latency (min.) 18.17 (12.60) 21.07 (19.87) 23.34 (21.16) 21.91 (19.83) 
 
n.s. 
36 
 
  
Objective Snoring Group 
 
Absent (A) Simple Snorers (SS) 
Sleep Disordered 
Breathing (SDB) Total 
Post-Hoc 
Group 
Differences 
Overall 
p 
 
(n=31) (n=82) (n=128) (n=241) 
Wake after sleep onset (min.) 47.76 (21.17) 57.23 (34.56) 60.51 (35.33) 57.76 (33.72) 
 
n.s. 
Total sleep time (min.) 389.24 (58.37) 372.71 (63.88) 366.30 (55.06) 371.43 (58.83) 
 
n.s. 
Sleep efficiency (%) 85.56 (5.38) 82.62 (9.09) 81.55 (8.22) 82.43 (8.30) A < SDB 0.052 
Stage 1 sleep (%) 6.04 (3.09) 7.34 (5.62) 8.12 (6.19) 7.59 (5.71) 
 
n.s. 
Stage 2 sleep (%) 66.85 (6.56) 64.99 (7.04) 64.44 (8.43) 64.94 (7.77) 
 
n.s. 
Delta sleep (%) 3.96 (4.30) 3.57 (4.28) 3.58 (4.52) 3.63 (4.40) 
 
n.s. 
REM sleep (%) 23.15 (5.02) 24.09 (4.60) 23.85 (4.71) 23.84 (4.70) 
 
n.s. 
No. of awakenings 19.86 (5.88) 20.35 (7.65) 19.74 (6.63) 19.96 (6.89) 
 
n.s. 
REM latency minus awake time 
(min.) 81.12 (39.80) 71.76 (28.45) 70.70 (37.49) 72.40 (35.05) 
 
n.s. 
Self-Reported Sleep Variables 
      Pittsburgh Sleep Quality Index 
(PSQI) 5.74 (3.05) 5.11 (2.81) 6.18 (3.35) 5.76 (3.17) SS < SDB 0.06 
Epworth Sleepiness Scale (ESS) 7.86 (4.59) 6.91 (3.77) 8.09 (4.22) 7.66 (4.14) 
 
n.s. 
Snoring Variables 
      Snoring index 0.036 (0.077) 0.668 (0.156) 0.658 (0.225) 0.581 (0.282)** A < SS & SDB 0.0001 
Snoring index – NREM 0.025 (0.092) 0.507 (0.259) 0.526 (0.273) 0.486 (0.288)** A < SS & SDB 0.0001 
Snoring index - REM 0.040 (0.080) 0.670 (0.192) 0.676 (0.231) 0.599 (0.289)** A < SS & SDB 0.0001 
Total snore count 10.23 (26.33) 719.82 (761.18) 1266.13 (1113.53) 
918.7 
(1017.97)** A < SS < SDB 0.0001 
Total snore count - NREM 7.61 (12.80) 608.57 (607.00) 1088.19 (954.94) 
794.58 
(863.27)** A < SS < SDB 0.0001 
Total snore count - REM 7.43 (21.79) 128.48 (220.26) 198.87 (216.30) 
161.41 
(216.33)** A < SS < SDB 0.002 
Self-reported snoring group 
      Don't Know 6 (20.0%) 30 (38.0%) 26 (21.0%) 62 (26.6%) 
 
0.0001 
Never 19 (63.3%) 29 (36.7%) 40 (32.3%) 88 (37.8%) 
  Infrequent (<3x/wk) 3 (10.0%) 14 (17.7%) 26 (21.0%) 43 (18.5%) 
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Objective Snoring Group 
 
Absent (A) Simple Snorers (SS) 
Sleep Disordered 
Breathing (SDB) Total 
Post-Hoc 
Group 
Differences 
Overall 
p 
 
(n=31) (n=82) (n=128) (n=241) 
Frequent (≥3x/wk) 2 (6.7%) 6 (7.6%) 32 (25.8%) 40 (17.2%) 
  Notes: *p<0.05; **p<0.01; ǂmean daily consumption reported across days of study; Δpercent of days any reported across study 
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 As expected, one-way ANOVAs revealed that the groups differed significantly on all 
anthropometric risk factors. Tukey’s LSD post-hoc analyses confirmed that the groups differed 
in a stepwise fashion, such that the Absent group had the lowest mean values for BMI, waist-hip 
ratio, and neck circumference, followed by the Simple Snorers and then the SDB group 
(p’s<0.001, Figure 4).  
 
 
 
 
Note: **p<0.01. All group means are significantly different from each other within each anthropometric measure. 
 
 
Figure 4. Body Mass Index (BMI) and Neck Circumference (cm) by Objective Snoring Group. 
 
 
 
The groups also differed on systolic blood pressure (SBP; p=0.002). Post-hoc analysis showed 
that both the SS and SDB groups had significantly higher SBP than the Absent group (p’s<0.01, 
Figure 5).  
 
20
25
30
35
40
45
Absent Simple Snorers Sleep Disordered
Breathing
An
th
ro
po
m
et
ric
 V
al
ue
Objective Snoring Group
BMI
Neck Circumference (cm)
**
**
39 
 
  
 
 
Note: **p<0.01. 
 
 
Figure 5. Mean Systolic Blood Pressure (mm/Hg) by Objective Snoring Group. 
 
 
 
Groups also differed on measures of metabolic risk, where the Absent group met significantly 
fewer criteria for the metabolic syndrome than either the SS or SDB groups (p<0.0001). Nearly 
one-third of the SS group (29%) and nearly one-half of the SDB group (45%) met criteria for 
metabolic syndrome diagnosis, significantly greater percentages than in the Absent group 
(p=0.002). The SS and SDB groups also met significantly greater number of metabolic syndrome 
criteria than the Absent group (p=0.0001, Figure 6).  
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Note: **p<0.01. 
 
 
Figure 6. Mean Number of Metabolic Syndrome Criteria Met by Objective Snoring Group. 
 
 
 
There were significant differences in key cardiovascular and cardiometabolic biomarker levels 
between the groups as well, with the SDB group showing the highest mean levels of CRP 
(p=0.0001), fasting glucose (p=0.006), and insulin (p=0.004). However, the Absent and SDB 
groups were more likely to have a physician-reported diagnosis of high blood pressure (p=0.001) 
or high cholesterol (p=0.005), compared to Simple Snorers. 
 There were few noteworthy differences among the groups for health behaviors, 
psychological variables, or PSG-assessed or self-reported sleep variables. The groups did not 
differ on menopausal status (X2=7.26, p=0.12) or indices of socioeconomic status (p’s>0.05). As 
expected, there were significant differences in the distribution of self-reported snoring frequency 
by objective snoring group designation (X2=25.17, p<0.0001). Figure 7 shows that 53.3% of the 
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 women who met criteria for SDB and almost 75% of simple snorers endorsed never snoring or 
not knowing that they snore. Only 7.6% of simple snorers endorsed clinically frequent snoring, 
despite the fact that these women snored 67% of their night on average, and had a mean of 720 
(± 761) scored snoring events on one night of sleep.
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 (A)  
(B)  
 
 
Figure 7. (A) Objective Snoring Group by Subjective Snoring Group Percentage. (B) Subjective 
Snoring Group by Objective Snoring Group Percentage. 
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5.2 CORRELATES OF SUBJECTIVE SNORING 
 
 
Of the 309 total Caucasian and African American women who participated in the SWAN Sleep 
Study, 300 of them had usable self-reported snoring data and were included in subjective snoring 
analyses (mean age 52.07 ± 2.13 years). The samples included in the objective and subjective 
snoring characterizations did not significantly differ from each other on key variables (p’s>0.05). 
Table 4 summarizes sample characteristics as a function of subjective snoring group category. 
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 Table 4. Characterization of Midlife Women by Subjective Snoring Group Designation. 
 
 
 
 Subjective Snoring Group 
 
Never  
(N) 
Don’t Know 
(DK) 
Infrequent 
(I) 
Frequent 
(F) Total 
Post-Hoc 
Group 
Differences 
Overall p 
 
(n=119) (n=76) (n=54) (n=51) (n=300) 
Demographic Variables Mean (S.D.) or n (%) Mean (S.D.) or n (%) Mean (S.D.) or n (%) Mean (S.D.) or n (%) Mean (S.D.) or n (%)     
Age (years) 52.11 (2.02) 51.82 (2.19) 52.25 (2.36) 52.15 (2.07) 52.07 (2.13) 
 
n.s. 
Race 
    
 
 
0.04 
Caucasian (%) 76 (45.2%) 36 (21.4%) 33 (19.6%) 23 (13.7%) 168 (56%) 
 
 
African American (%)* 43 (32.6%) 40 (30.3%) 21 (15.9%) 28 (21.2%) 132 (44%) 
 
 
Menopausal Status 
    
 
 
n.s. 
Premenopause / Early  
     menopause 78 (66.1%) 47 (61.8%) 33 (61.1%) 
 
184 (61.5%)   
Late peri-menopause (%) 20 (16.9%) 14 (18.4%) 12 (22.2%)  59 (19.7%)   
Postmenopause (%) 20 (16.9%) 15 (19.7%) 9 (16.7%)  56 (18.7%)   
Hormone replacement therapy 
use (%) 8 (6.8%) 4 (5.3%) 1 (1.9%) 2 (3.9%) 15 (5.0%)  n.s. 
Employment status 
    
 
 
n.s. 
Not employed (%) 18 (15.3%) 18 (23.7%) 9 (16.7%) 10 (19.6%) 55 (18.4%) 
 
 
Any employment (%) 100 (84.7%) 58 (76.3%) 45 (83.3%) 41 (80.4%) 244 (81.6%) 
 
 
Education level 
    
 
 
n.s. 
HS degree/some college (%) 55 (47.0%) 45 (60.0%) 24 (45.3%) 24 (49.0%) 148 (50.3%) 
 
 
College/postgraduate degree 
(%) 62 (53.0%) 30 (40.0%) 29 (54.7%) 25 (51.0%) 146 (49.7%) 
 
 
Income 
    
 
 
n.s. 
< $10,000 (%) 10 (8.5%) 7 (9.2%) 3 (5.6%) 1 (2.0%) 21 (7.0%) 
  $10,000 - 19,999 (%) 3 (2.5%) 4 (5.3%) 2 (2.7%) 1 (2.0%) 10 (3.3%) 
  $20,000 - 34,999 (%) 3 (2.5%) 5 (6.6%) 4 (7.4%) 5 (9.8%) 17 (5.7%) 
  $35,000 - 49,999 (%) 9 (7.6%) 11 (14.5%) 1 (1.9%) 9 (17.6%) 30 (10.0%) 
  $50,000 - 74,999 (%) 17 (14.4%) 10 (13.2%) 11 (20.4%) 5 (9.8%) 43 (14.4%) 
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 Subjective Snoring Group 
 
Never  
(N) 
Don’t Know 
(DK) 
Infrequent 
(I) 
Frequent 
(F) Total 
Post-Hoc 
Group 
Differences 
Overall p 
 
(n=119) (n=76) (n=54) (n=51) (n=300) 
$75,000 - 99,999 (%) 26 (22.0%) 17 (22.4%) 9 (16.7%) 14 (27.5%) 66 (22.1%) 
  $100,000 - 149,999 (%) 22 (18.6%) 12 (15.8%) 9 (16.7%) 6 (11.8%) 49 (16.4%) 
  > $150,000 (%) 17 (14.4%) 6 (7.9%) 13 (24.1%) 8 (15.7%) 44 (14.7%) 
  Physiological Variables 
    
 
  Body mass index (kg/m2)** 29.11 (6.82) 30.29 (5.68) 33.17 (8.56) 36.13 (9.70) 31.34 (7.87) 
N, DK < I, F 
I < F 0.0001 
Waist-to-hip ratio** 0.82 (0.07) 0.83 (0.07) 0.84 (0.08) 0.86 (0.08) 0.83 (0.73) N, DK < F 0.01 
Neck circumference (cm)** 35.15 (3.34) 35.93 (2.72) 37.75 (4.00) 39.04 (4.30) 36.47 (3.79) N, DK < I, F 0.0001 
Apnea-hypopnea index (AHI)** 6.35 (6.48) 5.98 (5.84) 11.89 (12.09) 28.62 (29.13) 11.02 (16.12) 
N, DK < I, F 
I < F 0.0001 
Systolic blood pressure 
(mm/Hg)** 
116.76 
(15.98) 122.74 (18.50) 117.91 (16.39) 
128.34 
(17.96) 
120.47 
(17.52) 
N < DK, F 
I < F 0.0001 
Diastolic blood pressure (mm/Hg) 72.38 (9.58) 75.38 (11.48) 73.10 (8.68) 76.12 (10.84) 73.91 (10.23) 
 
n.s. 
Vasomotor symptomsΔ 29.01 (35.54) 38.46 (36.53) 33.74 (31.94) 38.42 (35.72) 33.81 (34.10) 
 
n.s. 
No. metabolic syndrome criteria 
met 0.72 (1.02) 0.83 (1.17) 1.00 (1.00) 0.50 (0.71) 0.76 (0.99) 
 
n.s. 
Meets criteria for metabolic 
syndrome diagnosis (%) 1 (16.7%) 2 (13.3%) 0 (0.0%) 0 (0.0%) 3 (12.0%) 
 
n.s. 
Biomarkers 
    
 
  Average CRP (mg/dL)** 3.76 (5.18) 4.05 (4.63) 5.74 (6.70) 10.25 (10.31) 5.24 (6.81) N,DK,I < F 0.0001 
Glucose (mg/dL)** 87.23 (12.82) 88.70 (15.59) 92.26 (16.46) 
109.46 
(50.56) 92.30 (25.77) N,DK,I < F 0.0001 
Insulin (ulU/mL)** 11.63 (10.59) 13.35 (10.41) 18.32 (15.47) 22.51 (16.87) 15.18 (13.37) N,DK < I,F 0.0001 
Health Behavior Variables 
    
 
  ExerciseΔ 59.11 (31.80) 55.76 (32.57) 53.64 (31.51) 51.98 (35.25) 56.08 (32.48) 
 
n.s. 
Caffeineǂ 1.76 (1.39) 1.52 (1.28) 1.56 (1.19) 1.56 (1.41) 1.63 (1.33) 
 
n.s. 
Alcoholǂ 0.34 (0.51) 0.34 (0.63) 0.31 (0.50) 0.14 (0.30) 0.30 (0.52) 
 
n.s. 
Cigarettesǂ 0.66 (2.43) 1.09 (3.38) 0.94 (2.44) 1.44 (4.03) 0.95 (3.00) 
 
n.s. 
Sleep medication usageΔ 23.55 (41.11) 32.40 (46.18) 21.38 (40.23) 29.66 (45.07) 26.43 (42.97) 
 
n.s. 
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 Subjective Snoring Group 
 
Never  
(N) 
Don’t Know 
(DK) 
Infrequent 
(I) 
Frequent 
(F) Total 
Post-Hoc 
Group 
Differences 
Overall p 
 
(n=119) (n=76) (n=54) (n=51) (n=300) 
Passive smoking exposure 
    
 
 
n.s. 
0 person-hours (%) 63 (54.8%) 29 (38.7%) 24 (45.3%) 18 (38.3%) 134 (46.2%) 
  1-4 person-hours (%) 28 (24.3%) 25 (33.3%) 16 (30.2%) 19 (40.4%) 88 (30.3%) 
  >5 person-hours (%) 24 (20.9%) 21 (28.0%) 13 (24.5%) 10 (21.3%) 68 (23.4%) 
  Psychological Variables 
    
 
  IDS** 4.33 (2.48) 4.89 (2.90) 4.98 (2.75) 5.93 (3.43) 4.86 (2.86) N & DK < F 0.009 
IDS—no sleep variables* 2.35 (2.65) 2.89 (2.66) 2.94 (2.45) 3.80 (3.28) 2.84 (2.63) N < F 0.012 
Perceived Stress Scale 3.55 (2.74) 4.23 (2.76) 3.63 (2.57) 4.31 (2.52) 3.87 (2.69) 
 
n.s. 
State/Trait Anxiety Inventory 15.04 (4.41) 15.71 (4.83) 15.36 (4.15) 16.11 (4.93) 15.45 (4.56) 
 
n.s. 
Social support scale (scale 0-16) 13.60 (2.79) 12.97 (2.89) 13.37 (2.64) 13.41 (2.84) 13.37 (2.80) 
 
n.s. 
Bodily pain scale 72.67 (18.12) 74.01 (19.60) 67.02 (22.12) 66.25 (22.69) 70.90 (20.23) 
 
n.s. 
Quality of life scale (scale 0-10) 7.64 (1.67) 7.67 (1.61) 8.06 (1.11) 7.57 (1.64) 7.71 (1.56) 
 
n.s. 
Difficulty paying for basics 
    
 
 
n.s. 
Not hard at all (%) 89 (75.4%) 49 (64.5%) 39 (73.6%) 35 (70.0%) 212 (71.4%) 
  Somewhat / very hard (%) 29 (24.6%) 27 (35.5%) 14 (26.4%) 15 (30.0%) 85 (28.6%) 
  PSG-assessed Sleep Variables 
    
 
  Sleep latency (min.) 22.56 (22.20) 20.89 (15.40) 23.32 (26.06) 23.74 (21.24) 22.47 (21.23) 
 
n.s. 
Wake after sleep onset (min.) 52.41 (27.88) 63.07 (40.65) 54.40 (37.52) 55.60 (28.29) 56.02 (33.53) 
 
n.s. 
Total sleep time (min.) 
373.09 
(57.35) 376.35 (57.41) 362.94 (57.00) 
372.04 
(55.93) 
371.91 
(56.87) 
 
n.s. 
Sleep efficiency (%) 83.16 (8.72) 82.30 (7.49) 82.53 (9.04) 82.40 (7.53) 82.70 (8.26) 
 
n.s. 
Stage 1 sleep (%) 7.60 (5.72) 6.81 (3.71) 7.76 (7.24) 8.06 (5.79) 7.51 (5.61) 
 
n.s. 
Stage 2 sleep (%) 64.20 (7.37) 65.56 (6.69) 64.92 (7.43) 66.70 (7.44) 65.10 (7.24) 
 
n.s. 
Delta sleep (%) 3.63 (4.51) 3.67 (5.14) 3.70 (3.83) 2.95 (3.42) 3.54 (4.39) 
 
n.s. 
REM sleep (%)* 24.58 (4.61) 23.96 (5.26) 23.62 (4.50) 22.29 (4.55) 23.86 (4.80) N > F 0.04 
No. of awakenings 19.46 (6.44) 20.61 (7.47) 19.72 (7.66) 20.40 (6.66) 19.96 (6.96) 
 
n.s. 
REM latency minus awake time 
(min.) 
68.56 
(32.68) 77.60 (33.57) 72.98 (33.88) 
78.20 
(43.70) 
73.30 
(35.29) 
 
n.s. 
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 Subjective Snoring Group 
 
Never  
(N) 
Don’t Know 
(DK) 
Infrequent 
(I) 
Frequent 
(F) Total 
Post-Hoc 
Group 
Differences 
Overall p 
 
(n=119) (n=76) (n=54) (n=51) (n=300) 
Self-Reported Sleep Variables 
    
 
  Pittsburgh Sleep Quality Index 
(PSQI)* 5.10 (2.97) 6.03 (3.22) 6.34 (3.39) 6.41 (3.17) 5.78 (3.18) N < DK, I, F 0.024 
Epworth Sleepiness Scale 
(ESS)** 6.76 (3.69) 6.87 (3.82) 7.61 (4.11) 9.69 (4.74) 7.44 (4.12) N,DK,I < F 0.0001 
Snoring Variables 
    
 
  Snoring index** 0.53 (0.32) 0.53 (0.27) 0.65 (0.25) 0.69 (0.20) 0.58 (0.28) N,DK < I,F 0.002 
Snoring index - NREM** 0.55 (0.32) 0.54 (0.28) 0.67 (0.26) 0.71 (0.21) 0.60 (0.29) N,DK < I,F 0.003 
Snoring index – REM** 0.44 (0.30) 0.46 (0.31) 0.46 (0.24) 0.63 (0.22) 0.48 (0.29) N, DK, I < F 0.008 
Total snore count** 
619.97 
(764.5) 
638.38 
(813.25) 
1223.91 
(1101.6) 
1581.62 
(1254.96) 
901.42 
(1014.09) N,DK < I,F 0.0001 
Total snore count – NREM** 
547.30 
(633.61) 
522.21 
(656.32) 
1092.49 
(952.72) 
1334.00 
(1087.27) 
781.04 
(861.74) N,DK < I,F 0.0001 
Total snore count – REM** 
113.08 
(179.45) 
145.94 
(210.08) 
144.90  
(199.95) 
288.89 
(251.20) 
159.48 
(213.55) N, DK, I < F 0.001 
Objective snoring group*      - 0.024 
Absent 16 (21.9%) 6 (13.0%) 3 (9.1%) 1 (4.8%) 26 (15.0%)   
Simple snorers 25 (34.2%) 25 (54.3%) 12 (36.4%) 5 (23.8%) 67 (38.7%)   
Sleep disordered breathing 32 (43.8%) 15 (32.6%) 18 (54.5%) 15 (71.4%) 80 (46.2%)   
Notes: *p<0.05; **p<0.01; ǂmean daily consumption reported across days of study; Δpercent of days any reported across study.
48 
 
 Compared to Caucasian participants, a smaller percentage of African American participants 
endorsed never snoring (X2=8.32, p=0.04, Figure 8). 
 
 
 
 
 
 
Figure 8. Race Differences in Self-Reported Snoring Frequency. 
 
 
 
 Using ANOVA, we observed the hypothesized results for anthropometric measures, 
which were similar to differences found between objective snoring groups. Any snoring was 
associated with higher BMI (p=0.0001), neck circumference (p=0.0001), and AHI (p=0.0001) 
compared to Never or Don’t Know groups. Post-hoc tests of significant one-way ANOVAs 
revealed that only frequent snoring was correlated with higher SBP (p=0.0001), CRP 
(p=0.0001), and fasting glucose (p=0.0001). However, unlike objective snoring, self-reported 
snoring endorsement was not correlated with metabolic syndrome criteria. There was a trend for 
Frequent snorers to have a higher physician-reported rate of Type II diabetes (p=0.069). 
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 Compared to the other groups, Frequent snorers also had a higher rate of fair or poor perceived 
general health (p=0.0001), endorsed more depressive symptoms (p=0.009), and reported greater 
daytime sleepiness (p=0.0001). REM sleep percentage was the only PSG-assessed sleep variable 
to differ as a function of subjective snoring group, with Frequent snorers showing significantly 
less REM sleep than Never snorers (p=0.04). 
 
 
 
 
5.3 CRP 
 
 
As shown in Table 5, the full regression model accounting for age, race, menopausal status, 
average number of days between CRP blood draws and sleep study dates, mean daily servings of 
alcohol, passive smoking exposure, percent of study days on which sleep-affecting medication 
was used, and BMI revealed no significant associations between snoring index, AHI, and CRP 
levels (p>0.05, Figure 9).  
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 Table 5. Snoring Index and Apnea-Hypopnea Index are Not Associated with CRP in Midlife 
Women. 
 
 
 
 B SE p 
Step 1    
Race 0.095 0.153 0.53 
Age -0.016 0.035 0.65 
Menopausal status 0.073 0.103 0.48 
Average # days between 
CRP and sleep -0.001 0.0001 0.17 
Mean daily servings of 
alcohol across study -0.075 0.147 0.61 
Passive smoking exposure 
category 0.059 0.09 0.52 
Percent of days in which 
sleep-affecting medication 
used 0.001 0.002 0.52 
BMI 0.081** 0.011 0.0001 
Step 2    
AHI 0.006 0.007 0.38 
Snoring index (SI) 0.084 0.265 0.75 
Step 3    
SI x AHI -0.011 0.019 0.56 
Note: **p<0.01. 
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Note: Average CRP ≥10 mg/L excluded from analyses. 
 
 
Figure 9. Snoring Index and CRP by Race. 
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 There was no significant interaction effect of SI x AHI on CRP (p’s>0.05, Figure 10). These 
results did not change when the sample was restricted to exclude participants with CRP>10 mg/L 
in sensitivity analyses (p’s>0.05).  
 
 
 
 
Note: Average CRP ≥10 mg/L excluded from analyses. 
 
 
Figure 10. Association Between Snoring Index and CRP is Not Moderated by AHI. 
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  ANCOVA [between-subjects factor: objective snoring group (Absent, Simple Snorers, 
Sleep Disordered Breathing); covariates as listed above] revealed no main effects of objective 
snoring group on CRP, F(2,173)=0.235, p=0.791 (Figure 11). Again, BMI remained the only 
variable significantly associated with CRP level. 
 
 
 
 
Note: Average CRP ≥10 mg/L excluded from analyses. 
 
 
Figure 11. Objective Snoring Group and CRP by Race. 
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  ANCOVA [between-subjects factor: subjective snoring group (Never, Don't Know, 
Infrequent, Frequent); covariates as listed above] revealed no main effects of self-reported 
(subjective) snoring group on CRP, F(3,168)=1.259, p=0.29 (Figure 12). 
 
 
 
 
Note: Average CRP ≥10 mg/L excluded from analyses. 
 
 
Figure 12. Subjective Snoring Group and CRP by Race. 
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5.4 EXPLORATORY ANALYSES 
 
 
Since we had hypothesized that the relationship between snoring and CRP may be particularly 
important for postmenopausal women, we re-tested our SI model in the group of postmenopausal 
women only (n=41). As shown in Table 6, the full regression model accounting for age, race, 
average number of days between CRP blood draws and sleep study dates, mean daily servings of 
alcohol, passive smoking exposure, percent of study days on which sleep-affecting medication 
was used, and BMI revealed that snoring index (SI) was significantly associated with CRP 
(B=2.35, SE=0.97, p=0.025). Again, there was no main effect of AHI or SI by AHI interaction 
effect on CRP in the postmenopausal group. 
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 Table 6. Snoring Index but Not Apnea-Hypopnea Index is Associated with CRP in 
Postmenopausal Women. 
 
 
 B SE p 
Step 1    
Race -.347 .550 0.54 
Age .193 .128 0.15 
Average # days between 
CRP and sleep .0001 .001 0.81 
Mean daily servings of 
alcohol across study -1.634* .612 0.015 
Passive smoking exposure 
category .501 .320 0.13 
Percent of days in which 
sleep-affecting medication 
used .006 .006 0.36 
BMI .005 .038 0.90 
Step 2    
AHI .019 .031 0.55 
Snoring index (SI) 2.276* 1.017 0.037 
Step 3    
SI x AHI -.037 .103 0.73 
Note: *p<0.05. 
 
 
 
 We had hypothesized that race may moderate the relationship between SI and CRP. 
However, moderation analyses revealed no main effects of snoring index or race and no 
significant SI by race interaction effect on CRP. Secondary analysis of simple slopes revealed no 
significant differences in simple slopes between Caucasians and African Americans (Bdiff = 
0.191, t=0.464, p=0.64), suggesting that race is not a statistically significant moderator of 
snoring index and CRP (Figure 13). 
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Note: Fully adjusted model (covariates: age, menopausal status, average number of days between blood draws and 
sleep study night, mean daily alcohol consumption, passive smoking exposure, BMI). Average CRP ≥10 mg/L 
excluded from analyses. 
 
 
Figure 13. Associations Between Snoring Index and CRP are Not Significant and Not Moderated 
by Race.  
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6.0 DISCUSSION 
 
 
 
 
The present study evaluated associations among snoring and C-reactive protein in a multi-ethnic 
cohort of midlife women. We found no significant associations between snoring index and CRP 
in fully adjusted models. In the full sample, only BMI was significantly associated with CRP 
levels. However, in the group of postmenopausal women, we did find that snoring index was 
positively associated with CRP, supporting our hypothesis that snoring may be related to 
cardiovascular changes observed following the menopausal transition. 
 We proposed a conceptual physiological model of snoring-induced atherogenesis that 
may putatively underlie previously established associations among snoring and cardiovascular 
disease. Our model suggests that two components—a heightened inflammatory response and 
endothelial dysfunction—are associated in a bidirectional manner and maintained by nightly 
recurrence of snoring-induced oscillatory pressure waves. Ongoing inflammatory responses and 
dysfunction of the endothelium play important roles in atherogenesis (Libby, 2002; De Caterina 
et al., 1995; Smith et al., 1995; Rajavashisth et al., 1999) and are therefore possible pathways 
linking snoring and cardiovascular disease (CVD). We chose to investigate C-reactive protein 
because circulating levels are fairly stable within individuals across 24 hours, and it is an 
established nonspecific marker of inflammation (Visser et al., 1999; Libby, 2002). In a meta-
analysis of 7 prospective studies, moderately elevated CRP levels of 2.4 mg/L have been shown 
to predict future risk of coronary heart disease (Danesh et al., 1998). Even modest increases of 
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 CRP, within the upper clinical limit of 1 mg/L, have been associated with a 2- to 3-fold increased 
risk of adverse cardiovascular outcomes (Kuller et al., 1996; Ridker et al., 1998; Koenig et al., 
1999). On average, the women in our sample had a mean CRP level of 5.25 ± 6.87 mg/L, 
suggesting a disproportionate rate of heightened or even acute inflammation. While we feel that 
CRP remains an important inflammatory marker and worthy of investigation, it is plausible that 
any downstream effects of snoring-induced oscillatory pressure waves on inflammatory 
processes may be localized to the carotid artery, and therefore they may not be captured by a 
more global measure of inflammation like circulating CRP. 
 Additionally, the relationship between BMI and CRP is well-substantiated, with CRP a 
marker of elevated adiposity (Timpson et al., 2011). Our null findings in the overall sample may, 
therefore, largely be explained by BMI, given the mean BMI in our study of 31.69 ± 7.82, above 
the World Health Organization clinical cutoff for obesity of 30 (WHO, 1995). Obese women 
have a 4.76-fold increased risk of clinically raised CRP levels (95% CI=3.42-6.61; Visser et al., 
1999). In addition, larger individuals may simply display more snoring due to increased 
collapsibility of pharyngeal structures from adipose tissue weight. It is therefore plausible that 
the overwhelming associations between BMI and CRP in the present study may have obscured 
whatever associations may exist between objective snoring and CRP levels. Given these 
findings, future studies investigating the role of snoring and inflammation may benefit from 
including only normal weight women (BMI < 30), where a possible signal is less likely to be 
obscured by adiposity. 
 Our finding that snoring index is significantly associated with CRP in postmenopausal 
women is striking for two reasons. One, these women had a mean BMI even higher than the 
overall BMI in the full sample (postmenopausal: 32.91± 8.74). This suggests that the snoring 
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 index signal was strongest in these women, despite their increased adiposity. Two, the addition 
of AHI into the model did not attenuate this relationship, despite the high mean level of AHI in 
this group (14.02 ± 13.06). Together, these findings suggest that the snoring phenomenon 
contributes something to our understanding of cardiovascular risk in postmenopausal women 
above and beyond the well-established risk factors of obesity and sleep apnea. While only 17.1% 
of the postmenopausal group were Simple Snorers, our findings suggest that snoring may 
represent an important and understudied risk factor for postmenopausal women outside of 
traditional risk factors, such as smoking, SDB, low socioeconomic status, depression, or anxiety. 
In support of this, we found few significant differences between snoring groups on these risk 
factors, yet snoring was still associated with increased cardiovascular risk factors, particularly in 
the postmenopausal women. 
 It is of interest to note that AHI was not significantly associated with CRP in our study. 
Previous research has established that obstructive sleep apnea syndrome (OSAS) is an 
independent risk factor for cardiovascular disease (CVD) morbidity and mortality (Peker et al., 
1999; Leung et al., 2001; Kokturk et al., 2005; Lattimore et al., 2003). Given the mechanistic 
role of inflammatory processes in both OSAS and CVD, inflammatory markers have been a 
well-studied pathway linking apnea to CVD pathogenesis. Circulating CRP levels have been 
shown to be elevated in individuals with OSAS and CVD (Kokturk et al., 2005; Shamsuzzaman 
et al., 2002). One study found that median circulating CRP levels of OSA patients were 3.30 
mg/L, less than half of the sleep disordered breathing group mean CRP level of 6.94 ± 8.08 mg/L 
present in our study. Despite these elevated levels, and the fairly high mean AHI across our 
entire sample (11.20 ± 15.21), we did not find the expected association between AHI and CRP. 
Once again, it is plausible that the strength of BMI-related adiposity in our full sample fully 
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 attenuated any weaker relationships. In support of this explanation, researchers in Delhi recently 
found that obesity, and not OSA, was responsible for increased serum hsCRP levels in sleep 
disordered breathing patients (Sharma et al., 2008). 
 Despite the mixed results of our primary aims, we believe that our characterizations of 
the correlates of objective and subjective snoring are of merit and advance our understanding of 
what snoring looks like in midlife women. As we predicted, women who met clinical criteria for 
sleep disordered breathing did have the poorest physiological profiles, providing convergent 
support with the extant literature. However, our study is the first to identify characteristics of 
midlife women who are simple snorers. We found that these women had elevated systolic blood 
pressure and increased BMI, both established risk factors for CVD. Additionally, simple snorers 
met significantly more metabolic syndrome criteria than non-snorers and were more likely to 
meet criteria for the metabolic syndrome, findings that converge with Troxel and colleague’s 
(2010) reported association between loud snoring and the metabolic syndrome.  
 Simple Snorers did not differ from Absent snorers on conventional risk factors for 
snoring, such as cigarette smoking, passive smoking exposure, sleep medication usage, or 
exercise. Most importantly, Simple Snorers did not differ from Absent snorers on AHI 
(2.49±1.51 versus 2.46±1.31) but had significantly higher levels of snoring (719.82 ± 761.18 
versus 10.23 ± 26.33 total snore events), supporting the argument that simple snoring should be 
considered its own construct and separate from SDB.  
 Research on racial differences in prevalence has focused almost exclusively on sleep-
disordered breathing. To our knowledge, our study is the first to examine racial differences in 
objective snoring. Our study failed to replicate the differences in self-reported snoring and SDB 
between African Americans and Caucasians observed elsewhere (O’Connor et al., 2003; Redline 
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 et al., 1997; Scharf et al., 2004; Ram et al., 2010). The absence of racial differences in our 
sample may be interpreted as further support that simple snoring may be a separate construct 
from SDB. Because race may play a more important role in SDB than simple snoring, it is 
possible that craniofacial morphology is not the primary determinant of racial differences in 
SDB. Instead, factors such as BMI and socioeconomic status may largely be driving the higher 
rates of SDB in African Americans (Scharf et al., 2004). 
 
 
 
 
6.1 LIMITATIONS 
 
 
This study is the first to examine a possible pathway of snoring-induced inflammation that links 
objectively-scored snoring frequency to cardiovascular disease risk in midlife women. However, 
several limitations exist. Because snoring data were collected on one night of PSG recording, 
objective snoring variable could not be tested for inter-night reliability. In addition, the snore 
channel was not calibrated ahead of time to a standardized and consistent baseline voltage across 
participants, necessitating an individualized approach to establish a baseline for each participant. 
As a result, only relative changes in amplitude from baseline values were ascertained; absolute 
values of snore events could not be analyzed to determine whether greater vibration intensity was 
predictive of greater inflammation. However, no gold standard currently exists for snore channel 
scoring, whether calibrated or not, making it difficult to determine how much of a limitation this 
actually posed to this study.  
 Additionally, our overall null findings could suggest that injury resulting from snoring-
induced vibrations, if any, may be localized to the pharyngeal structures, and circulating 
measures might not capture any effects. Our study was limited in outcome measures available, 
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 and future studies should include multiple indices of cardiovascular risk. Alternatively, snoring-
induced vibrations may not be of sufficient amplitude or duration to induce endothelial injury in 
humans, despite the promising findings of the animal and cell models. Instead, a third factor 
related independently to both simple snoring and atherosclerosis may be at play. It is also 
possible that a single night of quantified objective snoring is not sufficiently representative of 
habitual snoring frequency. Prospective longitudinal studies of habitual snoring using objective 
methods are needed to address these research questions. To date, little is known about whether a 
single night of objectively scored snoring is representative of habitual snoring. 
 In addition, this study is a secondary data analysis of data collected during the SWAN 
Sleep Study and the temporally related Core SWAN Study. The participants were not screened 
for factors shown to be related to snoring and sleep disordered breathing, such as 
adenotonsillectomy, adenoidectomy, and tonsillectomy history, current upper airway or 
bronchial infection or inflammation, and facial, sinus, throat, and nasal surgery. Despite the 
fairly large sample size of women for whom objective snoring data were available (n=241), this 
study may have been underpowered to explore the relationship between primary snoring, 
independent of sleep apnea, and inflammation. 
 
 
 
6.2 IMPLICATIONS AND FUTURE DIRECTIONS 
 
 
Future studies should examine whether objectively scored snoring is associated with objective 
cardiovascular risk factors, such as carotid intramedial thickness (cIMT) and atherosclerotic 
plaque in the carotid artery. In particular, additional research examining the association between 
snoring and endothelial dysfunction is necessary to investigate whether the bidirectional 
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 inflammation-endothelial dysfunction model proposed in this study is supported. Such studies 
would do well to utilize objective measures of endothelial functioning, such as cIMT or coronary 
angiography, as well as additional measures of inflammation previously shown to be related to 
snoring and atherosclerosis, including TNF-∝ and IL-8. 
 Our comparisons of objective and subjective snoring groups provide evidence that self-
reported snoring is a poor measure of true snoring frequency, and our findings suggest that 
midlife women may not know the true extent of either their sleep disordered breathing or 
snoring. The substantial discrepancies between objective and self-reported snoring frequencies in 
this sample illustrate the need to measure snoring objectively in future studies.  
 To our knowledge, this study was the first to propose a possible mechanistic pathway of 
snoring vibration-induced atherogenesis and the first to investigate the relationship between 
objective snoring and a CVD risk inflammatory biomarker in midlife women. Women during the 
menopausal transition have been shown to be at increased risk for hypertension, coronary heart 
disease, and stroke (Lugaresi, Cirignotta, Coccagna, & Piana, 1975; Norton & Dunn, 1985; Hu et 
al., 2000). Concurrently, the prevalence of nocturnal snoring increases as women transition 
through midlife and the menopause (National Sleep Foundation, 2007). While we did not find 
the expected associations between nighttime percentage of snoring and CRP in our entire sample 
of midlife women, we did find the hypothesized relationship in postmenopausal women. Overall, 
our findings suggest that snoring may represent a unique and understudied variable linking 
nocturnal physiology to increased CVD risk and atherosclerosis in postmenopausal women.
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APPENDIX A 
 
 
 
 
F-SCORE VALUES FOR TRAINEE SCORERS COMPARED TO GOLD-TRUTH SCORER 
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Note:  P = Precision, R = Recall, F = F-score. Nan = not a number. 
 
 
Figure 14. F-score Values for Trainee Scorers Compared to Gold-Standard Ground Truth Scorer.   
0
0.2
0.4
0.6
0.8
1
F-
sc
or
e
Scorer
511037
0
0.2
0.4
0.6
0.8
1
F-
sc
or
e
Scorer
513031
0
0.2
0.4
0.6
0.8
1
F-
sc
or
e
Scorer
513052
0
0.2
0.4
0.6
0.8
1
F-
sc
or
e
Scorer
511009
0
0.2
0.4
0.6
0.8
1
F-
sc
or
e
Scorer
511006
0
0.2
0.4
0.6
0.8
1
F-
sc
or
e
Scorer
511070
0
0.2
0.4
0.6
0.8
1
F-
sc
or
e
Scorer
513094
0
0.2
0.4
0.6
0.8
1
F-
sc
or
e
Scorer
514061
0
0.2
0.4
0.6
0.8
1
F-
sc
or
e
Scorer
517043
0
0.2
0.4
0.6
0.8
1
F-
sc
or
e
Scorer
517072
67 
 
  
 
 
 
 
APPENDIX B 
 
 
 
 
PRECISION, RECALL, AND F-SCORE VALUES FOR RELIABILITY FILES 
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 Table 7. Table of Precision, Recall, and F-score Values for Six Scorers Across 11 Reliability Files. 
 
Note: P=Precision, R=Recall, F=F-score, Nan=not a number. 
 
 
  
511037 513031 513052 511009 511006 511070 513079 513094 514061 517043 517072 
 
  P R F P R F P R F P R F P R F P R F P R F P R F P R F P R F P R F 
Ground 
truth 1 
Expert 2 .85 .91 .88 .95 .93 .94 .91 .66 .77 .97 .82 .89 .89 .89 .89 .33 .25 .28 0 0 Nan .87 .90 .88 .94 .91 .93 .97 .94 .96 .95 .93 .94 
Expert 3 .83 .86 .84 .95 .92 .93 .94 .84 .89 .97 .81 .88 .78 .93 .85 .28 .50 .36 Nan 0 Nan .78 .98 .87 .82 .99 .90 .95 .96 .95 .93 .95 .94 
Expert 4 .90 .87 .88 .97 .97 .97 .83 .93 .88 .95 .90 .92 .85 .92 .88 Nan 0 Nan 0 0 Nan .86 .92 .89 .92 .97 .94 .97 .98 .98 .90 .96 .93 
Expert 5 .86 .87 .86 .97 .96 .97 .80 .89 .84 .87 .94 .90 .72 .99 .83 0 0 Nan .25 1 .40 .78 .97 .87 .81 .99 .89 .94 .98 .96 .88 .99 .93 
Expert 6 .93 .79 .85 .92 .97 .94 .74 .96 .83 .90 .96 .93 .77 .95 .85 .50 .50 .66 0 0 Nan .79 .97 .87 .63 .84 .72 .95 .97 .96 .84 .99 .91 
Ground 
truth 2 
Expert 1 .91 .85 .88 .93 .95 .94 .66 .91 .77 .82 .97 .89 .89 .89 .89 .25 .33 .28 0 0 Nan .90 .87 .88 .91 .94 .93 .97 .94 .96 .93 .95 .94 
Expert 3 .85 .83 .84 .95 .95 .95 .71 .87 .78 .90 .90 .90 .77 .92 .84 .28 .66 .40 Nan 0 Nan .78 .93 .84 .79 .98 .87 .95 .96 .95 .91 .96 .93 
Expert 4 .95 .85 .90 .94 .92 .93 .63 .96 .76 .86 .98 .92 .82 .88 .85 Nan 0 Nan .50 1 .66 .89 .92 .90 .88 .97 .92 .97 .98 .98 .89 .98 .93 
Expert 5 .88 .84 .86 .95 .93 .94 .58 .89 .70 .76 .97 .85 .72 .99 .83 0 0 Nan .25 1 .40 .79 .95 .86 .77 .98 .86 .94 .98 .96 .86 .99 .92 
Expert 6 .92 .73 .81 .87 .93 .90 .52 .92 .67 .78 1 .88 .73 .99 .84 .33 .33 .33 .25 1 .40 .78 .91 .84 .62 .83 .71 .95 .97 .96 .82 .99 .90 
Ground 
truth 3 
Expert 1 .86 .83 .84 .92 .95 .93 .84 .94 .89 .81 .97 .88 .93 .78 .85 .50 .28 .36 0 Nan Nan .98 .78 .87 .99 .82 .90 .94 .97 .96 .95 .93 .94 
Expert 2 .83 .85 .84 .95 .95 .95 .87 .71 .78 .90 .90 .90 .92 .77 .84 .66 .28 .40 0 Nan Nan .93 .78 .84 .98 .79 .87 .94 .97 .95 .96 .91 .93 
Expert 4 .88 .81 .85 .95 .97 .96 .74 .92 .82 .84 .96 .89 .84 .76 .80 Nan 0 Nan 0 Nan Nan .91 .79 .85 .98 .87 .96 .95 .98 .96 .91 .95 .93 
Expert 5 .80 .79 .80 .92 .95 .94 .68 .85 .76 .73 .94 .82 .86 .99 .92 .50 .14 .22 0 Nan Nan .92 .92 .92 .91 .93 .94 .91 .98 .94 .89 .98 .93 
Expert 6 .93 .76 .83 .88 .95 .91 .66 .95 .78 .76 .98 .86 .83 .95 .88 .66 .28 .40 0 Nan Nan .93 .91 .92 .67 .92 .91 .92 .97 .94 .86 .99 .92 
Ground 
truth 4 
Expert 1 .87 .90 .88 .97 .97 .97 .93 .83 .88 .90 .95 .92 .92 .85 .88 0 Nan Nan 0 0 Nan .92 .86 .89 .97 .92 .94 .98 .97 .98 .96 .90 .93 
Expert 2 .85 .95 .90 .92 .94 .93 .96 .63 .76 .98 .86 .92 .88 .82 .85 0 Nan Nan 1 .50 .66 .92 .89 .90 .97 .88 .92 .98 .95 .96 .98 .89 .93 
Expert 3 .81 .88 .85 .97 .95 .96 .92 .74 .82 .96 .84 .89 .76 .84 .80 0 Nan Nan Nan 0 Nan .79 .91 .85 .87 .98 .92 .96 .96 .96 .95 .91 .93 
Expert 5 .82 .87 .84 .89 .90 .90 .89 .89 .89 .85 .97 .90 .75 .95 .84 0 Nan Nan .25 .50 .33 .81 .93 .86 .85 .98 .91 .85 .98 .96 .93 .98 .96 
Expert 6 .93 .82 .87 .91 .96 .93 .84 .97 .90 .87 .98 .92 .80 .98 .88 0 Nan Nan .25 .50 .33 .82 .92 .87 .65 .86 .74 .96 .97 .96 .89 .99 .94 
Ground 
truth 5 
Expert 1 .87 .86 .86 .96 .97 .97 .89 .80 .84 .94 .87 .90 .99 .77 .85 0 0 Nan 1 .25 .40 .97 .78 .87 .99 .81 .89 .98 .94 .96 .99 .88 .93 
Expert 2 .84 .88 .86 .93 .95 .94 .89 .58 .70 .97 .76 .85 .99 .73 .84 0 0 Nan 1 .25 .40 .95 .79 .86 .98 .77 .86 .98 .91 .94 .99 .86 .92 
Expert 3 .79 .80 .80 .95 .92 .94 .85 .68 .76 .94 .73 .82 .99 .83 .88 .14 .50 .22 Nan 0 Nan .92 .92 .92 .93 .91 .92 .93 .90 .91 .98 .89 .93 
Expert 4 .87 .82 .84 .90 .89 .90 .89 .89 .89 .97 .85 .90 .95 .80 .88 Nan 0 Nan .50 .25 .33 .93 .81 .86 .98 .85 .91 .98 .95 .96 .98 .93 .96 
Expert 6 .93 .78 .85 .92 .97 .95 .83 .96 .89 .93 .92 .92 .93 .93 .93 .33 .50 .40 .50 .50 .50 .94 .92 .93 .67 .94 .78 .98 .95 .96 .94 .98 .96 
Ground 
truth 6 
Expert 1 .79 .93 .85 .97 .92 .94 .96 .74 .83 .96 .90 .93 .95 .77 .85 .50 .66 .57 0 0 Nan .97 .79 .87 .84 .63 .72 .97 .95 .96 .99 .84 .91 
Expert 2 .73 .92 .81 .93 .87 .90 .92 .52 .67 1 .78 .88 .99 .73 .84 .33 .33 .33 1 .25 .40 .91 .78 .84 .83 .62 .71 .97 .92 .94 .99 .82 .90 
Expert 3 .76 .93 .83 .95 .88 .91 .95 .66 .78 .98 .76 .86 .95 .83 .88 .28 .66 .40 Nan 0 Nan .91 .93 .92 .92 .67 .78 .96 .94 .95 .99 .86 .92 
Expert 4 .82 .93 .87 .96 .91 .93 .97 .84 .90 .98 .87 .92 .98 .80 .88 Nan 0 Nan .50 .25 .33 .92 .82 .87 .86 .65 .74 .97 .96 .96 .99 .89 .94 
Expert 5 .78 .93 .85 .97 .92 .95 .96 .83 .89 .92 .93 .92 .93 .93 .93 .50 .33 .40 .50 .50 .50 .92 .94 .93 .94 .67 .78 .95 .98 .96 .98 .94 .96 
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